Document:

Exhibit

EXHIBIT 10.1

Separation Agreement
This Separation Agreement (“Agreement”) is made and entered into by and between Neil McFarlane (hereinafter “Employee”), and Retrophin, Inc., a Delaware corporation (hereinafter the “Company”). 
WHEREAS, Employee currently serves a Chief Operating Officer of the Company;
WHEREAS, Employee’s employment with the Company will terminate effective May 31, 2019;
WHEREAS, Employee and the Company are parties to that certain Employment Agreement, dated August 15, 2016, by and between Employee and the Company, as amended on April 11, 2017 (as amended, the “Employment Agreement”); and
WHEREAS, Employee and the Company desire to resolve all claims and issues that have, or could have been raised, in relation to Employee’s employment with the Company and arising out of or in any way related to the acts, transactions or occurrences between Employee and the Company to date, including, but not limited to, Employee’s employment with the Company or the conclusion of that employment, on the terms set forth below; 
NOW, THEREFORE, in consideration of the premises and mutual promises contained in this Agreement, and other valuable consideration to which Employee is not otherwise entitled, the receipt and sufficiency of which are hereby acknowledged, it is agreed by the parties as follows: 
1.Termination of Employment.  Employee hereby acknowledges and agrees that his employment as an officer and employee of the Company and/or as an officer, employee or director of its subsidiaries, as applicable, will terminate effective as of May 31,  2019 (the “Separation Date”).
2.Consideration.  As a material inducement to and in consideration for Employee entering into this Agreement, and subject to the terms and conditions of this Agreement and the Employment Agreement, the Company agrees as follows: 
a.Effective as of the Separation Date, Employee will be entitled to receive the benefits set forth in Section 6.5(b)(i), Section 6.5(b)(ii), Section 6.5(b)(iii) and Section 6.5(b)(iv) of the Employment Agreement.  For the avoidance of doubt, with respect to the benefits set forth in Section 6.5(b)(iii), Employee acknowledges and agrees that (i) all outstanding Stock Awards with performance-based vesting held by Employee for which the relevant performance period ends within the 12-month period following the Separation Date shall remain eligible for vesting during such 12-month period as though Employee had continued to render continuous service to the Company throughout such period, and such Stock Awards with performance-based vesting shall vest (if applicable) based on actual performance during such performance period and (ii) on the 12-month anniversary of the Separation Date, all unvested Stock Awards with performance-based vesting then-held by Employee shall automatically expire and terminate.
b.Effective immediately prior to the Separation Date, the post-termination exercise period during which Employee may exercise Employee’s vested stock options following the Separation Date (which, under the terms of such options, is three months following the Separation Date) shall be extended to May 31, 2020, subject to earlier termination in the event of a change in control or corporate transaction as set forth in the terms of the equity incentive plan under which the equity awards were granted. Except to the extent provided in this Section 2, the Employee’s stock options will continue to be subject to the terms and conditions of the equity plans and stock option grant notices and agreements pursuant to which they were granted.
3.Release.  As a condition to the benefits provided in this Agreement to which Employee would not otherwise be entitled, Employee agrees to execute and return to the Company the General Release attached as Exhibit A to the Employment Agreement (the “Release”), and to allow the Release to become effective. 
4.No Other Entitlements.  Except for the compensation, monies and benefits expressly set forth in Section 2, Employee acknowledges that he is not entitled to any other compensation, monies or benefits from the Company, including but not limited to bonuses, commissions,  or other forms of compensation or benefits, repayments of debts, or reimbursements of expenses. 
5.Post-Termination Obligations.  All payments and benefits to Employee under Section 2 of this Agreement shall be subject to Employee’s compliance with the following provisions following the Separation Date: 
a.Confidential Information.  Employee remains bound by the obligations set forth in the Confidentiality Agreement that he executed with the Company (the “CDA”).  In addition, Employee agrees that he will promptly  return and deliver to the Company all documents, data and other materials and items in his possession, custody or control, wherever located, that belong to the Company and/or contain or reflect Confidential Information, including, but not limited to, any and all keys, credit cards, security cards, computer software, disks, data, records, notebooks, correspondence, customer or supplier lists, files, forms, supplies or other documents or materials, in any form or format and including, but not limited to, any printed versions or copies or other recordings of such documents or materials, that have been 

provided or furnished to Employee by the Company or its affiliates, or have been obtained or developed or used by Employee during the performance of Employee’s services for the Company, or in connection with Employee’s services or any other activities for the Company.  Employee agrees that prior to responding to any valid subpoena, court order or other legal process which would require disclosure of Confidential Information encompassed by this paragraph, he shall give the Company prior written notice of the subpoena, court order or other legal process in sufficient time to afford the Company a reasonable opportunity to challenge the subpoena, court order or other legal process.  
b.Transition Assistance.  Employee shall, upon reasonable notice, furnish such information and assistance to the Company as may reasonably be required by the Company in connection with the transition of Employee’s duties to other individuals at the Company.
c.Failure to Comply.  In the event that Employee shall fail to comply with any provision of this Section 5, and such failure shall continue for ten (10) days following delivery of notice thereof by the Company to Employee, all rights of Employee and any person claiming under or through him to payments and benefits under paragraphs (a) and (b) of Section 2 of this Agreement shall thereupon terminate and no person shall be entitled thereafter to receive any such payments or benefits.  In addition, in the event of a breach or threatened breach by Employee of the provisions of this Section, the Company shall have and may exercise any and all other rights and remedies available to the Company at law or otherwise, including but not limited to obtaining an injunction from a court of competent jurisdiction enjoining and restraining Employee from committing such violation, and Employee hereby consents to the issuance of such injunction.   
6.Employment Agreement Amendment.  Upon execution of this Agreement, Article 6, Section 6.8(a) of the Employment Agreement shall be, and hereby is, amended such that the reference to “three (3) months” is replaced with “six (6) months”.
7.Section 409A Compliance.  To the extent applicable, the parties hereto intend that this Agreement be exempt from, or if an exemption is not available, comply with Section 409A of the Internal Revenue Code of 1986, as amended and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”).  The parties hereby agree that this Agreement shall at all times be construed in a manner to be exempt from, or if an exemption is not available, to comply with, Section 409A. The parties also agree that in no event shall any payment required to be made pursuant to this Agreement that is considered deferred compensation within the meaning of Section 409A and is not otherwise exempt from the provision thereof be accelerated in violation of Section 409A. The parties further agree that any payment paid in connection with this Agreement pursuant to the Employment Agreement will be paid at the same time or times and subject to the same conditions as in the Employment Agreement, and will be otherwise paid in accordance with the provisions of the Employment Agreement as if the Employee’s employment had been terminated by the Company without Cause (as defined in the Employment Agreement).
8.Taxes.  The Company does not represent or guarantee that any particular federal or state income, payroll or other tax treatment will result from this Agreement or the compensation or benefits payable pursuant to this Agreement.  Employee is solely responsible for the proper tax reporting and timely payment of any income tax or interest for which he is liable as a result of this Agreement and the compensation or benefits payable pursuant to this Agreement.
9.No Attachment.  No right to receive payments under this Agreement shall be subject to set off, offset, anticipation, commutation, alienation, sale, assignment, encumbrance, charge, pledge or hypothecation or to execution, attachment, levy or similar process or assignment by operation of law, and  any attempt, voluntary or involuntary, to effect any such action shall be null, void and of no effect.
10.Miscellaneous.  This Agreement shall be binding upon and inure to the benefit of Employee, his assigns, heirs, executors, administrators and representatives, as well as the predecessors, successors, purchasers and assigns of the Company. Employee may not assign any of his rights or delegate any of his duties under this Agreement. Except as preempted by federal law, this Agreement shall be governed by and construed in accordance with the laws of the State of California, without reference to its conflict of law provision. Any number of counterparts of this Agreement may be signed and delivered, each of which shall be considered an original and all of which, together, shall constitute one and the same instrument. 
11.Entire Agreement.  This Agreement, the CDA and the Employment Agreement comprise the entire agreement and understanding of the parties with respect to the subject matter, specifically including but not limited to any terms and conditions of employment or the termination of employment, or any other service agreements between the parties, and there are no agreements or understandings other than those contained herein. Further, this Agreement is intended to be a binding contract among the parties hereto and shall not be modified, except by writing signed by both Employee and the Company.  The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any provision (or part thereof) of this Agreement shall in no way affect the validity or enforceability of any other provisions (or remaining part thereof).

EMPLOYEE ACKNOWLEDGES AND AGREES THAT EMPLOYEE HAS CAREFULLY READ AND FULLY UNDERSTANDS ALL THE PROVISIONS OF THIS AGREEMENT. EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE HAS NOT RELIED UPON ANY REPRESENTATION OR STATEMENT, WRITTEN OR ORAL, WHICH IS NOT SET FORTH IN THIS DOCUMENT. EMPLOYEE FURTHER ACKNOWLEDGES THAT EMPLOYEE IS ENTERING INTO THIS AGREEMENT VOLUNTARILY AND OF EMPLOYEE’S OWN FREE WILL, WITHOUT ANY COERCION FROM ANY PERSON, INCLUDING THE COMPANY OR ANY OF ITS REPRESENTATIVES. EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE FULLY AND COMPLETELY UNDERSTANDS THE TERMS AND CONDITIONS OF THIS AGREEMENT AND HAS VOLUNTARILY AND KNOWINGLY AGREED TO SUCH TERMS AND CONDITIONS.

IN WITNESS WHEREOF, the parties have executed this Separation Agreement on this the 19th day of April, 2019.

	
		
	EMPLOYEE
	 

	 
	 

	/s/ Neil McFarlane
	 

	Neil McFarlane
	 

	 
	 

	RETROPHIN, INC.
	 

	 
	 

	/s/ Laura Clague
	 

	Laura Clague
	 

	Chief Financial OfficerEXPLANATORY NOTE: [*] INDICATES THE PORTION OF THIS EXHIBIT
THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED.

 

Exhibit 10.10

 

 

 

OPTION AND LICENSE AGREEMENT

 

This
Option and License Agreement is made as of March 21, 2016 (the “Execution Date”) by and between
Aptose Biosciences Inc., a Canadian corporation having a place of business
at 5955 Airport Road, Suite 228, Mississauga, Ontario, L4V 1R9, Canada (“Aptose”) and CrystalGenomics,
Inc., a South Korean corporation having a place of business at 5th F. Bldg. A,
Korea Bio Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 Korea (“CG”). Aptose
and CG are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

Recitals

 

Whereas,
CG is a science-driven biopharmaceutical company that is developing and marketing human therapeutics, and has been developing novel
inhibitors of the Bruton’s Tyrosine Kinase (“BTK”) family of kinases as cancer therapies, including
its proprietary compound referred to as CG026806 (“CG’806”);

 

Whereas,
Aptose is a science-driven biotechnology company advancing first-in-class therapeutics to treat life-threatening cancers;

 

Whereas,
pursuant to that certain Materials Transfer Agreement between CG and Aptose, dated October 8, 2015 (the “MTA”),
CG has provided Aptose with quantities of CG’806 to conduct certain validation studies, which studies are ongoing as of the
Execution Date and will continue through the Evaluation Period (as defined in Section 2.1 below), and during such Evaluation Period,
Aptose has a right to obtain from CG an exclusive option for an exclusive license to research, develop and commercialize Licensed
Compounds (as defined in Section 1.40 below) in all countries of the world except China, South Korea and North Korea;

 

Whereas,
based on the results of the validation studies during the Evaluation Period, Aptose will determine if it desires to continue preclinical
development of CG’806 or other BTK inhibitors by paying the option grant fee described in Article 2, and upon payment of
such option grant fee, CG desires to grant to Aptose, and Aptose desires to receive from CG, an exclusive option for an exclusive
license referred to in the foregoing recital paragraph, and the Parties will enter the Option Period (as defined in Section 3.1
below);

 

Whereas,
contingent on the results of the preclinical studies during the Option Period, Aptose will determine if it desires to continue
clinical development and commercialization of Licensed Compounds by paying the option exercise fee, and upon payment of such option
exercise fee, CG desires to grant Aptose, and Aptose desires to receive from CG, an exclusive license referred to in the foregoing
recital paragraph, on the terms and conditions set forth in this Agreement, and the Parties will enter the License Period (as defined
in Section 4.1 below).

 

Now
Therefore, in consideration of the foregoing and the covenants and promises contained herein, the Parties agree as follows:

    	 	1	 

     

    

article
1 

 

Definitions

 

As used herein, the following terms shall
have the following meanings:

 

1.1             
“Additional Materials” has the meaning set forth in Section 2.3 (Activities During Evaluation
Period).

 

1.2             
“Additional Studies” has the meaning set forth in Section 2.3 (Activities During Evaluation
Period).

 

1.3             
“Advisory Committee” has the meaning set forth in Section 5.2(a)(i) (Establishment).

 

1.4             
“Affiliate” means, with respect to a Party, any company or entity controlled by, controlling,
or under common control with such Party. For the purposes of this definition, the word “control” (including, with correlative
meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly
or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity,
whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.

 

1.5             
“Agreement” has differing meanings depending on whether the Parties are in the Evaluation
Period, Option Period or License Period and shall accordingly be interpreted to mean: (i) while the Evaluation Period is in effect,
Article 2 and those provisions expressly stated to be operative by Section 2.7 only; (ii) if and when the Option Period comes into
effect, Articles 2 and 3 and those provisions expressly stated to be operative by Sections 2.7 and 3.10 only; and (iii) if and
when the License Period comes into effect, all provisions of this Option and License Agreement between the Parties dated the Execution
Date.

 

1.6             
“Applicable Laws” means the applicable provisions of any and all national, supranational,
regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments,
decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, arbitrator or Governmental Authority having
jurisdiction over or related to the subject item.

 

1.7             
“Aptose Data” means all Data generated in connection with any research, Development, regulatory,
manufacturing or Commercial activities with respect to any Licensed Compound or Product conducted by or on behalf of Aptose or
its Affiliates or Sublicensees (including activities conducted by CG in response to Aptose’s request to conduct certain Development
activities for Licensed Compounds or Products in the Field in the Licensed Territory as set forth in Section 5.4).

 

1.8             
“Aptose Program Technology” has the meaning set forth in Section 8.1(a) (Aptose Program Technology).

    	 	2	 

     

    

1.9             
“Aptose’s Right of First Refusal” has the meaning set forth in Section 4.3 (Right of
First Refusal).

 

1.10         
“Aptose Studies” has the meaning set forth in Section 2.3 (Activities During Evaluation Period).

 

1.11         
“CG Data” means all Data generated in connection with any research, Development, regulatory,
manufacturing or Commercial activities with respect to any Licensed Compound or Product conducted by or on behalf of CG or its
Affiliates (other than activities conducted by CG under Section 5.4) or licensees other than Aptose or Aptose’s Affiliates.

 

1.12         
“CG Intellectual Property” means the CG Know-How and CG Patents.

 

1.13         
“CG Know-How” means all Information (including CG Data) Controlled by CG or its Affiliates
as of the Effective Date or during the Term that relates to the composition, method of use, mechanism of action or method of manufacture
of any Licensed Compound.

 

1.14         
“CG Notice” has the meaning set forth in Section 4.3 (Right of First Refusal).

 

1.15         
“CG Patent” means any Patent that (a) is Controlled by CG or its Affiliates as of the Effective
Date or during the Term, and (b) relates to the composition, method of use, mechanism of action or method of manufacture
of any Licensed Compound; and, as to any Patent in Joint Technology, such Patent to the extent of CG’s interest. The CG Patents
existing as of the Effective Date are set forth on Exhibit A attached hereto.

 

1.16         
“Combination Product” means: (a) a pharmaceutical product that contains a Licensed Compound
and at least one other clinically active ingredient that is not a Licensed Compound; or (b) any combination of a Product and another
pharmaceutical product that contains at least one other clinically active ingredient that is not a Product, where such products
are not formulated together but are sold together as a single product and invoiced as one product. The other clinically active
ingredient(s) in clause (a) and the other pharmaceutical product(s) in clause (b) are each referred to as the “Other
Product(s)”.

 

1.17         
“Commercialization” means the marketing, promotion, sale and/or distribution of Products,
and all related manufacturing activities not included in the definition of Development. Commercialization shall include commercial
activities conducted in preparation for Product launch. “Commercialize” has a correlative meaning.

 

1.18         
“Commercially Reasonable Efforts” means those efforts that are consistent with the efforts
and resources normally used by a biotechnology company of similar size to Aptose in the research and development of a potential
product or the commercialization of a product, in each case owned by it or to which it has exclusive rights, with similar product
characteristics as a Product and of similar market potential at a similar stage in its development or product life as the Product,
taking into account all relevant factors, including patent coverage, safety and efficacy, product profile, competitiveness of the
marketplace, proprietary position and profitability (including pricing and reimbursement).

    	 	3	 

     

    

1.19         
“Competing Product” means any product that contains a compound, other than a Licensed Compound,
that (a) has an in vitro IC50 for inhibiting BTK of less than 10 nM and (b) has an in vitro IC50 for inhibiting
FLT3-ITD (i.e., internal tandem duplications of FLT3) of less than 10 nM, in each case (a) and (b) as determined by the protocol
set forth in Exhibit B.

 

1.20         
“Confidential Information” means, with respect to a Party, all Information of such Party that
is disclosed to the other Party under this Agreement, whether disclosed in oral, written, graphic, or electronic form, but excluding
Information described in Section 9.2 (Exceptions). All confidential information disclosed by a Party under the Confidential Disclosure
Agreement between the Parties dated February 10, 2015 (the “Prior CDA”), and all confidential information
disclosed by CG under the MTA, shall be deemed to be such Party’s Confidential Information hereunder. The terms and conditions
of this Agreement shall be deemed to be both Parties’ Confidential Information, and each Party shall have the obligations
set forth in Article 9 (Confidentiality) with respect thereto.

 

1.21         
“Control” means, with respect to any material, Information, or intellectual property right,
that a Party owns or has a license to such material, Information, or intellectual property right and, in each case, has the ability
to grant to the other Party access, a license, or a sublicense (as applicable) to the foregoing on the terms and conditions set
forth in this Agreement without violating the terms of any agreement or other arrangement with any Third Party in existence and
in effect prior to the Effective Date.

 

1.22         
“Cover” means, with respect to a Product and a claim of a CG Patent in any country in the
Licensed Territory, that such claim would be infringed, absent a license, by the manufacture, use, offer for sale, sale or importation
of such Product in such country; and “Covering” has the corresponding meaning.

 

1.23         
“Data” means any and all scientific, technical or test data pertaining to any Licensed Compound
or Product that is generated under this Agreement, including research data, clinical pharmacology data, CMC data (including analytical
and quality control data and stability data), preclinical data, clinical data or submissions made in association with an IND or
MAA with respect to any Licensed Compound or Product.

 

1.24         
“Develop” or “Development” means all activities that relate to the
development of Licensed Compounds and Products or to (a) obtaining, maintaining or expanding Regulatory Approval of a Product,
or (b) developing the ability to manufacture clinical and commercial quantities of a Licensed Compound or Product. This includes:
(i) preclinical testing, toxicology, and clinical trials; (ii) preparation, submission, review, and development of data or information
for the purpose of submission to a Governmental Authority to obtain, maintain or expand Regulatory Approval of a Product; and (iii)
manufacturing process development and scale-up, bulk production and fill/finish work associated with the supply of a Product for
preclinical testing and clinical trials, and related quality assurance and technical support activities. “Develop”
has a correlative meaning.

 

1.25         
“Development Plan” has the meaning set forth in Section 5.3 (Development Plan).

    	 	4	 

     

    

1.26         
“Dollar” means a U.S. dollar, and “$” shall be interpreted accordingly.

 

1.27         
“Effective Date” has the meaning set forth in Section 2.5 (Option Grant).

 

1.28         
“EMA” means the European Medicines Agency or any successor entity thereto.

 

1.29         
“Evaluation Period” has the meaning set forth in Section 2.1 (Evaluation Period).

 

1.30         
“Execution Date” has the meaning set forth in the first paragraph above.

 

1.31         
“Executive Officers” has the meaning set forth in Section 13.3 (Internal Resolution).

 

1.32         
“FDA” means the U.S. Food and Drug Administration or any successor agency thereto.

 

1.33         
“Field” means all fields of use, including the diagnosis, prognosis, prevention and treatment
of all diseases and conditions.

 

1.34         
“First Commercial Sale” means the first sale to a Third Party of a Product in a given regulatory
jurisdiction after Regulatory Approval has been obtained in such jurisdiction.

 

1.35         
“Generic Product” means, with respect to a Product in a particular regulatory jurisdiction,
any pharmaceutical product that (a) (i) contains the same active pharmaceutical ingredients as such Product for the same route
of administration as such Product and is approved by the Regulatory Authority in such country; or (ii) is A/B Rated (defined below)
with respect to such Product or otherwise approved by the Regulatory Authority in such country as a substitutable generic for such
Product; and (b) is sold in such jurisdiction by a Third Party that is not a Sublicensee and did not purchase such product from
Aptose or its Affiliates or Sublicensees. For purposes of this definition, “A/B Rated” means, for the
U.S., “therapeutically equivalent” as determined by the FDA, applying the definition of “therapeutically equivalent”
set forth in the preface to the then-current edition of the FDA publication “Approved Drug Products With Therapeutic Equivalence
Evaluations” and, for outside the U.S., such equivalent determination by the applicable Regulatory Authority.

 

1.36         
“Governmental Authority” means any national, international, federal, state, provincial or
local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled
to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, or any court
or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).

 

1.37         
 “IND” means any investigational new drug application, clinical trial application, clinical
trial exemption or similar or equivalent application or submission for approval to conduct human clinical investigations.

 

1.38         
“Indication” means a human disease
or medical condition that is approved by a Regulatory Authority to be included as a discrete claim (as opposed to a subset of a
claim) in the labeling of a Product based on the results of a separate Pivotal Clinical Trial(s) sufficient to support Regulatory
Approval of such claim; provided, however, that with respect to oncology Indications, a particular oncology Indication will be
considered distinct from another oncology Indication only if it is for a different tumor type or for a different hematological
malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myelogenous
leukemia), and will not be considered distinct from another oncology Indication if it is only a different line of therapy.

    	 	5	 

     

    

1.39         
“Information” means any data, results, and information of any type whatsoever, in any tangible
or intangible form, including, without limitation, know-how, trade secrets, practices, techniques, methods, processes, inventions,
developments, specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise),
software, algorithms, marketing reports, expertise, stability, technology, test data including pharmacological, biological, chemical,
biochemical, toxicological, and clinical test data, analytical and quality control data, stability data, studies and procedures.

 

1.40         
“Initiation” means, with respect to a clinical trial, first dosing of the first subject in
such clinical trial.

 

1.41         
“Joint Technology” has the meaning set forth in Section 8.1(b)
(Joint Technology).

 

1.42         
“Licensed Compound” means: (i) CG’806; (ii) any other compound whose composition, manufacture
or use is claimed by a claim in the patents and patent applications set forth in Exhibit A; and (iii) any other compound
that employs or embodies Know-How Controlled by CG or its Affiliates in existence on or before the Effective Date and
that relates to the composition, method of use, mechanism of action or method of manufacture of any inhibitor of any kinase within
the BTK family of kinases.

 

1.43         
“License Period” has the meaning set forth in Section 4.1 (License Grant and License Period).

 

1.44         
“Licensed Territory” means worldwide except the Retained Territory.

 

1.45         
“Major European Country” means any of the following countries: France, Germany, Italy, Spain
and the United Kingdom.

 

1.46         
“Marketing Authorization Application” or “MAA” means an application
to the appropriate Regulatory Authority for approval to market a Product (but excluding Pricing Approval) in any particular jurisdiction,
including an NDA in the U.S.

 

1.47         
“Materials” has the meaning set forth in Section 5.11 (Materials Transfer).

 

1.48         
“MHLW” means the Japanese Ministry of Health, Labour and Welfare or any successor entity thereto.

 

1.49         
“MTA” has the meaning set forth in the recitals.

    	 	6	 

     

    

1.50         
“MTA Studies” has the meaning set forth in Section 2.3 (Activities During Evaluation Period).

 

1.51         
“NDA” means a New Drug Application, as defined in the United States Federal Food, Drug and
Cosmetic Act, as amended, and applicable regulations promulgated thereunder by the FDA.

 

1.52         
“Net Sales” means, with respect to any Product, the gross amounts invoiced by Aptose and its
Affiliates and Sublicensees for sales of such Product in the Licensed Territory to unaffiliated Third Parties, less the following
deductions provided to unaffiliated entities and actually allowed and taken:

 

(a)              
cash, trade or quantity discounts, charge-back payments, including administrative fees in connection therewith, and
rebates actually granted to trade customers, retail pharmacy chains, wholesalers, managed health care organizations, pharmaceutical
benefit managers, insurers, group purchasing organizations and national, state, or local government;

 

(b)              
credits, rebates or allowances actually allowed upon prompt payment or on account of claims, damaged goods, rejections
or returns of Products, including in connection with recalls, and the actual amount of any write-offs for bad debt (provided that
any amount subsequently recovered will be treated as Net Sales);

 

(c)               
reasonable distributors’ fees in connection with Products;

 

(d)              
freight, postage, shipping, transportation and insurance charges, in each case actually allowed or paid, for delivery
of Products; and

 

(e)               
taxes (other than income taxes), duties, tariffs, mandated contributions or other governmental charges levied on the
sale of Products, including VAT, excise taxes, sales taxes, and a pro rata portion of pharmaceutical excise taxes imposed on sales
of pharmaceutical products as a whole and not specific to Products (such as those imposed by the U.S. Patient Protection and Affordable
Care Act of 2010, Pub. L. No. 111-148, as amended).

 

Notwithstanding the
foregoing, amounts received or invoiced by Aptose or its Affiliates or Sublicensees for the sale of Products among Aptose and its
Affiliates and Sublicensees shall not be included in the computation of Net Sales hereunder. Net Sales shall be accounted for in
accordance the selling party’s standard practices in the relevant country in the Licensed Territory.

 

Notwithstanding the
foregoing, “Net Sales” shall not include any amounts invoiced for sales of Products supplied for use in clinical trials
of Products, or under compassionate use, named patient or other charitable programs for which net sales do not exceed cost of goods.

 

Net Sales for a Combination
Product in a country shall be calculated as follows:

 

(i)                
If a Product containing the same Licensed Compound as in the Combination Product, as its sole active ingredient, and
the Other Product(s) each are sold separately in such country, Net Sales will be calculated by multiplying the total Net Sales
(as described above) of the Combination Product by the fraction A/(A+B), where A is the public or list price in such country of
such Product sold separately in the same formulation and dosage, and B is the (sum of the) public or list price(s) in such country
of the Other Product(s) sold separately in the same formulation and dosage, during the applicable calendar year.

    	 	7	 

     

    

(ii)             
If such Product is sold independently of the Other Product(s) in such country, but the public or list price of the Other
Product(s) cannot be determined, Net Sales will be calculated by multiplying the total Net Sales (as described above) of such Combination
Product by the fraction A/C, where A is the public or list price in such country of such Product sold independently and C is the
public or list price in such country of the Combination Product, during the applicable calendar year.

 

(iii)           
If the Other Product(s) are sold independently of the Licensed Compound in the Combination Product in such country,
but the public or list price of a Product containing such Licensed Compound cannot be determined, Net Sales will be calculated
by multiplying the total Net Sales (as described above) of such Combination Product by the fraction [1-B/C], where B is the (sum
of the) public or list price(s) in such country of the Other Product(s) and C is the public or list price in such country of the
Combination Product, during the applicable calendar year.

 

(iv)            
If neither the public or list price of the Other Product(s) nor the public or list price of such Product can be determined
in such country, then the Parties shall discuss the amount to be included in Net Sales, based on a reasonable allocation of the
relative values of the Other Product(s) and such Product, and if they fail to agree, the allocation will be submitted to an independent
Third Party expert mutually agreed by the Parties; but if either Party disagrees with such determination, the Parties may resolve
this dispute by arbitration in accordance with Section 13.4 below.

 

1.53         
“Option” has the meaning set forth in Section 3.1 (Option Grant and Option Period).

 

1.54         
“Option Exercise Fee” has the meaning set forth in Section 3.8 (Option Exercise).

 

1.55         
“Option Grant Fee” has the meaning set forth in Section 2.5 (Option Grant).

 

1.56         
“Option Period” has the meaning set forth in Section 3.1 (Option Grant and Option Period).

 

1.57         
“Partnership Review Committee” has the meaning set forth in Section 5.2(b)(i) (Establishment).

 

1.58         
“Patents” means all patents and patent applications (which for the purpose of this Agreement
shall be deemed to include certificates of invention and applications for certificates of invention), including all divisionals,
continuations, substitutions, continuations-in-part, re-examinations, reissues, additions, renewals, revalidations, extensions,
registrations, pediatric exclusivity periods and supplemental protection certificates and the like of any such patents and patent
applications, and any and all foreign equivalents of the foregoing.

    	 	8	 

     

    

1.59         
“Phase 1 Clinical Trial” means a human clinical trial of a Product, the principal purpose
of which is to evaluate safety in healthy individuals or patients, to determine pharmacokinetic parameters and other key pharmaceutical
properties of the Product (including absorption, metabolism, and elimination), or to determine the appropriate range of doses to
evaluate in further clinical trials, in each case as described in 21 C.F.R. § 312.21(a), as amended from time to time, or
the corresponding foreign regulations.

 

1.60         
“Phase 2 Clinical Trial” means a human clinical trial of a Product, the principal purpose
of which is to evaluate the effectiveness and/or safety of such Product in the target patient population, as described in 21 C.F.R.
§ 312.21(b), as amended from time to time, or the corresponding foreign regulations.

 

1.61         
“Pivotal Clinical Trial” means a pivotal human clinical trial of a Product (whether or not
denominated a “Phase 3” clinical trial under applicable regulations) with a defined dose or a set of defined doses
of such Product designed to ascertain efficacy and safety of such Product for the purpose of enabling, without the performance
of additional human clinical trials, the preparation and submission of an MAA to the applicable Regulatory Authorities in a country
of the Licensed Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the
corresponding foreign regulations.

 

1.62         
“Pricing Approval” means such governmental approval, agreement, determination or decision
establishing prices for a Product that can be charged and/or reimbursed in regulatory jurisdictions where the applicable Governmental
Authorities approve or determine the price and/or reimbursement of pharmaceutical products.

 

1.63         
“Product” means any pharmaceutical product that contains a Licensed Compound as an active
ingredient, alone or with one or more other active ingredients, including all forms, presentations, doses and formulations.

 

1.64         
“Product Infringement” has the meaning set forth in Section 8.3(a) (Patent Enforcement).

 

1.65         
“Product Trademark” has the meaning set forth in Section 8.4 (Trademarks).

 

1.66         
“Regulatory Approval” means all approvals necessary for the manufacture, marketing, importation
and sale of a Product for one or more indications in a country or regulatory jurisdiction, including satisfaction of all applicable
regulatory and notification requirements and receipt of all required Pricing Approvals.

 

1.67         
“Regulatory Authority” means any Governmental Authority that has responsibility in its applicable
jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer
for sale, sale or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA, EMA and MHLW.

 

1.68         
“Regulatory Filing” means all applications, filings, submissions, approvals, licenses, registrations,
permits, notifications and authorizations (or waivers) with respect to the testing, Development, manufacture or Commercialization
of any Licensed Compound or Product made to or received from any Regulatory Authority in a given country, including any INDs and
MAAs.

    	 	9	 

     

    

1.69         
“Retained Territory” means China, South Korea and North Korea.

 

1.70         
“Royalty Term” has the meaning set forth in Section 7.2(b) (Royalty Term).

 

1.71         
“Safety Data” means Data related solely to any adverse drug experiences and serious adverse
drug experiences as such information is reportable to Regulatory Authorities in the Licensed Territory or Retained Territory. Safety
Data also includes “adverse events”, “adverse drug reactions” and “unexpected adverse drug reactions”
as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited
Reporting.

 

1.72         
“Securities Laws” means all applicable securities laws in all provinces of Canada and the
respective rules, regulations, blanket orders and blanket rulings under such laws, together with applicable published policies,
policy statements and notices of the applicable securities commission or securities regulatory authority in all provinces of Canada.

 

1.73         
“Sublicensee” means a Third Party that has received a sublicense from Aptose to some or all
of the rights granted to Aptose under Section 4.5 (Sublicenses).

 

1.74         
“Term” has the meaning set forth in Section 12.1 (Term).

 

1.75         
“Third Party” means a person or entity other than CG or Aptose or an Affiliate of either of
them.

 

1.76         
“United States” or “U.S.” means the United States of America
and its territories and possessions.

 

1.77         
“Valid Claim” means a claim of an issued patent in the CG Patents, which claim has not (a)
lapsed, been cancelled, become abandoned, or been declared invalid or unenforceable by an unappealed or unappealable decision or
judgment of a court of competent jurisdiction, or (b) been admitted to be invalid or unenforceable through reissue or disclaimer.

 

article
2 

 

Evaluation
Period

 

2.1             
Evaluation Period. This Article 2 shall take effect from and after the Execution Date, and except as expressly set forth
in this Article 2, no other provision of this Agreement shall be of any force or effect. During the Evaluation Period (defined
herein), Aptose will conduct certain studies of CG’806 as described in this Article 2 for the purpose of generating data
that Aptose will use to determine whether it desires to obtain an option to the CG Intellectual Property. The “Evaluation
Period” means the period of time that commenced on the date that the MTA came into effect and ends upon the earlier
of: (i) sixteen (16) weeks after Aptose’s receipt of the Additional Materials under Section 2.3 (Activities During Evaluation
Period) below, or such later date as the Parties may agree in writing; and (ii) Aptose’s payment of the Option Grant Fee
in accordance with Section 2.5 (Option Grant) below.

    	 	10	 

     

    

2.2             
Exclusive Evaluation. CG hereby covenants to Aptose that, during the Evaluation Period, neither CG nor its Affiliates
will grant or offer any license or other rights to a Third Party, or otherwise discuss or negotiate with any Third Party the terms
of any such license or rights, with respect to the research, development, manufacture or commercialization of any Licensed Compound
or Product.

 

2.3             
Activities During Evaluation Period. As of the Execution Date, Aptose is conducting the studies using CG’806 that
are described in Exhibit B of the MTA (the “MTA Studies”). During the Evaluation Period, Aptose
will have the right to conduct additional studies of CG’806 to obtain data useful to determine whether to pay the Option
Grant Fee (the “Additional Studies” and collectively with the MTA Studies, the “Aptose Studies”).
As of the Execution Date, Aptose has received an additional fifteen grams (15g) of CG’806 (the “Additional Materials”)
to conduct the Additional Studies. Aptose will reimburse CG for the amount charged by CG’s contract manufacturer to manufacture
and supply the Additional Materials.

 

2.4             
Access to Data. Following completion of the first MV4-11 subcutaneous xenograft Aptose Study, Aptose shall provide to
CG all data, results and information generated from such study (but not other Aptose Studies conducted prior to the Effective Date).

 

2.5             
Option Grant. At any time prior to the expiration of the Evaluation Period, Aptose may pay to CG a one-time fee of one
million U.S. Dollars ($1,000,000) (the “Option Grant Fee”), and the date on which Aptose makes such payment
will be referred to as the “Effective Date”. No additional payments are due from Aptose to CG during
the Evaluation Period other than payments associated with Additional Materials under Section 2.3 (Activities During the Evaluation
Period). Upon Aptose’s payment of the Option Grant Fee, CG agrees to grant, and hereby grants, Aptose: (i) the Option (as
specified in Section 3.1, below), and (ii) the preclinical development license in Section 3.2, below, and the Parties shall thereupon
enter the Option Period as set forth in Article 3, below. For clarity, Aptose is under no obligation to pay the Option Grant Fee,
and Aptose’s failure to pay the Option Grant Fee is not a breach of this Agreement and will not give rise to any right or
remedy of CG except as expressly set forth herein.

 

2.6             
Effects of Aptose’s Failure to Pay Option Grant Fee. If Aptose fails to pay the Option Grant Fee by the end of
the Evaluation Period, or elects by written notice to CG not to pay the Option Grant Fee at any time prior to the end of the Evaluation
Period, then:

 

(a)              
Aptose will transfer and assign, and hereby transfers and assigns, to CG or its designee all data, results and information
generated from the Aptose Studies, including the Aptose Data, and Aptose will fulfill its obligations under this Section 2.6(a)
without any additional payment by CG or any other obligation; provided that Aptose may retain one copy of such data, results and
information for archival purposes only, subject to continuing confidentiality obligations as set forth in Section 12.7 and Article
9 below; and

    	 	11	 

     

    

(b)             
all provisions in this Article 2 (and this Agreement), other than Aptose’s obligations set forth in Section 2.6(a)
above and in Section 2.7 below as applicable, will terminate and cease to be of any further force or effect.

 

2.7             
Applicable Definitions and Provisions. Only defined terms from the recitals and Article 1 that are used in this Article
2 apply, and include the following terms: CG’806 (recitals), MTA (recitals), Additional Materials (Section 1.1), Additional
Studies (Section 1.2), Affiliate (Section 1.4), Agreement (Section 1.5), Aptose Studies (Section 1.10), CG Intellectual Property
(Section 1.12), CG Know-How (Section 1.13), CG Patent (Section 1.15), Effective Date (Section 1.27), Evaluation Period (Section
1.29), Execution Date (Section 1.30), Information (Section 1.39), Licensed Compound (Section 1.42), MTA Studies (Section 1.50),
Option (Section 1.53), Option Grant Fee (Section 1.55), Product (Section 1.63), and Third Party (Section 1.77). Further, the following
provisions of this Agreement apply to this Article 2 and are in effect during the Evaluation Period: Article 9 (Confidentiality),
Section 10.3 (Additional Representations and Warranties), Article 13 (Governing Law; Dispute Resolution), Section 14.1 (Notices),
Section 14.7 (Assignment), Section 14.8 (Limitation of Liability), Section 14.9 (Performance by Affiliate), Section 14.10 (No Strict
Constructions; Headings), Section 14.11 (Further Assurances), Section 14.12 (English Language), and Section 14.13 (Counterparts).
Sections 2.6, 2.7, 14.1, 14.7, 14.8, 14.10 and 14.12 and Articles 9 and 13 will survive termination of this Agreement under Section
2.6(b).

 

article
3 

 

Option
Period

 

3.1             
Option Grant and Option Period. Upon Aptose’s payment of the Option Grant Fee, this Article 3 comes into effect
for the duration of the Option Period (defined below), and except as expressly set forth in this Article 3, no other provision
of this Agreement shall be of any force or effect. CG hereby grants to Aptose an exclusive option to obtain an exclusive license
to Develop and Commercialize Licensed Compounds and Products in the Licensed Territory as set forth in Section 4.4 (the “Option”).
CG hereby covenants to Aptose that, during the Option Period, neither CG nor its Affiliates will grant or offer any license or
other rights to a Third Party, or otherwise discuss or negotiate with any Third Party the terms of any such license or rights,
with respect to the research, development, manufacture or commercialization of any Licensed Compound or Product in the Licensed
Territory. The “Option Period” means the period of time commencing on the date Aptose pays the Option
Grant Fee to CG and ending upon the earlier of: (i) the first filing of an IND for a Product by Aptose or its Affiliate; (ii) the
first dosage of a Product in a human subject by Aptose or its Affiliate; (iii) payment of the Option Exercise Fee as specified
in Section 3.8; and (iv) eighteen (18) months after the date the Option Period commences (i.e., eighteen (18) months after payment
of the Option Grant Fee), unless extended pursuant to Section 3.6 (Diligence).

 

3.2             
Preclinical Development License. Upon Aptose’s payment of the Option Grant Fee, CG agrees to grant, and hereby
grants, Aptose a co-exclusive (with CG) license, with a right to sublicense in accordance with Section 3.3 (Sublicenses) below,
under the CG Intellectual Property for the duration of the Option Period, to preclinically develop, including to make, have made,
use, import and export, Licensed Compounds and Products in the Field in the Licensed Territory solely for the purposes of conducting
preclinical development or preparing for clinical development of Licensed Compounds and Products (including manufacturing clinical
supplies of Licensed Compounds and Products), but excluding the right to file an IND for a Product or conduct human clinical trials
of a Product. No additional license or rights are granted to Aptose during the Option Period other than as expressly set forth
in this Article 3. Subject to Section 3.1, CG retains the right under CG Intellectual Property to also preclinically develop Licensed
Compounds and Products throughout the world.

    	 	12	 

     

    

3.3             
Sublicenses. Aptose shall have the right to grant sublicenses under any or all rights granted in Section 3.2 (Preclinical
Development License) to its Affiliates and to Third Parties, subject to CG’s prior written consent, such consent not to be
unreasonably withheld, and on an as-needed basis, such sublicenses may be approved by CG, such approval not to be unreasonably
withheld, to be granted through multiple tiers. Each such sublicense shall be effective only to the extent each remains fully consistent
with the terms and conditions of this Article 3 and this Agreement (if the Parties enter the License Period).

 

3.4             
Activities During Option Period. During the Option Period, the Parties will set up an Advisory Committee, and Aptose
will prepare a draft Development Plan for development of Licensed Compounds and Products in the Field in the Licensed Territory
as described in Sections 5.2(a) (Advisory Committee) and 5.3 (Development Plan) below. If the Option Period ends or Aptose elects
not to pay the Option Exercise Fee before the end of the Option Period, then the Advisory Committee shall disband; however, if
Aptose pays the Option Exercise Fee, then the activities of the Advisory Committee shall continue into the License Period under
the Partnership Review Committee as and to the extent set forth in Section 5.2(b) below.

 

3.5             
Technology Transfer and Access to Data. 

 

(a)              
By CG. Promptly after the commencement of the Option Period,
CG shall provide to Aptose or its designee all CG Know-How then in existence that is necessary or useful for Aptose to exercise
the license granted in Section 3.2 (Preclinical Development License) above. At least once per calendar quarter during the Option
Period, CG shall provide to Aptose or its designee all CG Know-How, including CG Data, generated since the last such disclosure
(if any) that is necessary or useful for Aptose to exercise the license granted in Section 3.2 above. During the Option Period,
CG shall furnish Aptose with electronic copies of, and if reasonably requested by Aptose, physical access to the originals of,
any and all documents, electronic records, databases and other tangible materials included in the CG Know-How. As reasonably requested
by Aptose, during the Option Period, CG shall provide, at no additional cost to Aptose, reasonable technical support (by teleconference,
by electronic means or in-person at CG’s or its contractor’s facilities during regular business hours and upon reasonable
advance notice, as needed) to support such technology transfer. Aptose shall have the right to incorporate CG Data in
any pre-IND filings and the first IND filing for a Product in the Licensed Territory and to cross-reference Regulatory Filings
Controlled by CG in the Retained Territory, and otherwise exercising its rights or fulfilling its obligations under this Article
3.

 

(b)             
By Aptose. On a semiannual
basis after the commencement of the Option Period, Aptose shall provide CG with copies of or access to all Aptose Data not previously
provided to CG pursuant to the Advisory Committee meeting schedule in Section 5.2. CG shall have the right to use Aptose Data as
necessary to seek to obtain and maintain Regulatory Approval for Products in the Retained Territory, including the right
to incorporate Aptose Data in Regulatory Filings with Regulatory Authorities in the Retained Territory and to cross-reference Regulatory
Filings Controlled by Aptose in the Licensed Territory, and otherwise
to exercise its rights or fulfill its obligations under this Agreement.

    	 	13	 

     

    

3.6             
Diligence. Aptose agrees to use Commercially Reasonable Efforts to preclinically develop at least one Licensed Compound
or Product and to obtain acceptance for filing and review of an IND for a Product in the Licensed Territory within eighteen (18)
months after the commencement of the Option Period. The Parties acknowledge and agree that the Option Period: (a) will be extended
automatically by the amount of any delay resulting from (i) clinical or regulatory delays that are outside of Aptose’s reasonable
control, including requests or requirements of a Regulatory Authority beyond what would be reasonably anticipated, or (ii) delays
in developing a novel formulation of Product with increased bioavailability or manufacturing needed quantities of such formulation
that are outside of Aptose’s reasonable control; and (b) may otherwise be extended by prior mutual written consent.

 

3.7             
Exclusivity. CG hereby covenants that, during the Option Period, neither it nor its Affiliates will (a) grant or offer
any license or other rights to a Third Party, or otherwise discuss or negotiate with any Third Party the terms of any license or
rights, (b) conduct any activities, whether independently or with or for the benefit of a Third Party, or (c) file any patent applications,
in each case (a)-(c) with respect to the research, development, manufacture or commercialization of any Competing Product.

 

3.8             
Option Exercise.

 

(a)              
Payment or Issuance of Shares. At any time prior to the expiration of the Option Period, Aptose may by giving written
notice to CG exercise its Option. Promptly thereafter, Aptose shall either (i) pay to CG two million U.S. Dollars ($2,000,000)
in cash, (ii) issue to CG the equivalent of two million U.S. Dollars ($2,000,000) of common stock of Aptose in accordance with
Applicable Laws, or (iii) pay to CG one million U.S. Dollars ($1,000,000) in cash and issue to CG the equivalent of one million
U.S. Dollars ($1,000,000) of common stock of Aptose in accordance with Applicable Laws ((i), (ii) or (iii), as applicable, the
“Option Exercise Fee”), and the election of clause (i), (ii) or (iii) will be at Aptose’s sole
discretion. Upon such payment and/or issuance, Aptose will be granted the license set forth in Section 4.4 (Commercial License
Grant) below, and the Parties will enter the License Period. The deemed value per share of such common stock (the “Shares”)
will equal the volume weighted average trading price of the common stock of Aptose on the Toronto Stock Exchange (calculated by
dividing the total value of common stock traded by the total volume of common stock traded for the applicable period) for the ten
(10) trading days ending on the trading day prior to the date of issuance, and the number of shares to be issued to CG shall equal
one million U.S. Dollars ($1,000,000) or two million U.S. Dollars ($2,000,000), as applicable, divided by such deemed value per
share, rounded up to the nearest whole number. For clarity, the license grant in Section 4.4 (Commercial License Grant) constitutes
the consideration for the Shares, and no other purchase price shall be payable.

    	 	14	 

     

    

(b)             
Representations and Warranties. In connection with the issuance of the Shares upon Aptose’s exercise of the Option,
Aptose hereby represents, warrants and, as applicable, covenants to CG, as of the Effective Date, that:

 

(i)                
upon exercise of the Option in accordance with the terms of this Agreement, the Shares will be (A) duly authorized and
allotted for issuance; (B) validly issued and fully paid and non-assessable; and (C) once issued, freely tradeable after the expiry
of applicable hold periods and compliance with resale restrictions and conditions under the Securities Laws and the Applicable
Laws of any other relevant jurisdiction.

 

(ii)             
Aptose is a reporting issuer or the equivalent in all provinces of Canada and is not on a list of defaulting issuers
maintained by applicable securities commissions or securities regulatory authorities in any of the provinces of Canada pursuant
to applicable Securities Laws; in particular, Aptose is in compliance, in all material respects, with all of its applicable continuous
disclosure obligations under Securities Laws; and

 

(iii)           
Aptose will, within the required time, file with the Toronto Stock Exchange any documents, reports and information,
in the required form, required to be filed by applicable Securities Laws in connection with the issuance of the Shares upon exercise
of the Option, together with any applicable filing fees and other materials.

 

3.9             
Effects of Aptose’s Failure to Exercise Option. If Aptose fails to exercise its Option within the Option Period,
including paying the Option Exercise Fee by the end of the Option Period, or elects by written notice to CG not to pay the Option
Exercise Fee at any time prior to the end of the Option Period, then:

 

(a)              
Aptose will transfer and assign, and hereby transfers and assigns, to CG or its designee all data, results and information
generated from the Aptose Studies and preclinical development activities, including all Aptose Data and all data, results and information
that are reasonably necessary for CG to continue the development and commercialization of the Licensed Compounds and Products,
and Aptose will fulfill its obligations under this Section 3.9(a) without any additional payment by CG or any other obligation;
provided that Aptose may retain one copy of such data, results and information for archival purposes only, subject to continuing
confidentiality obligations as set forth in Section 12.7 and Article 9 below; and

 

(b)             
all provisions in Article 2 and this Article 3, other than Aptose’s obligations set forth in Section 3.9(a) above
and Section 3.10 below as applicable, will terminate and forthwith cease to be of any force or effect.

 

3.10         
Applicable Definitions and Provisions. Only defined terms set forth in Section 2.7 (Applicable Definitions and Provisions)
above, and defined terms from Article 1 that are used in this Article 3 apply, and include the following terms: CG’806 (recitals),
Advisory Committee (Section 1.3), Affiliate (Section 1.4), Applicable Laws (Section 1.6), Aptose Data (Section 1.7), CG Data (Section
1.11), CG Intellectual Property (Section 1.12), CG Know-How (Section 1.13), CG Patent (Section 1.15), Commercialize (Section 1.17),
Control (Section 1.21), Data (Section 1.23), Develop (Section 1.24), Development Plan (Section 1.25), Field (Section 1.33), IND
(Section 1.37), Licensed Compound (Section 1.42), License Period (Section 1.43), Licensed Territory (Section 1.44), Option Exercise
Fee (Section 1.54), Option Grant Fee (Section 1.55), Option Period (Section 1.56), Product (Section 1.63), Regulatory Approval
(Section 1.66), Regulatory Authority (Section 1.67), Regulatory Filings (Section 1.68), Retained Territory (Section 1.69), Sublicensee
(Section 1.73), and Third Party (Section 1.75). Further, the following provisions of this Agreement apply to this Article 3 and
are in effect during the Option Period: Section 5.2 (Advisory Committee), Section 5.3 (Development Plan), Article 8 (Intellectual
Property), Article 9 (Confidentiality), Article 10 (Representations and Warranties), Article 11 (Indemnification), Article 12 (Term;
Termination), Article 13 (Governing Law; Dispute Resolution), and Article 14 (General Provisions). Sections 3.9, 3.10, 8.1, 10.4,
14.1, 14.7, 14.8, 14.10 and 14.12 and Articles 9, 11 and 13 will survive termination of this Agreement under Section 3.9(b).

    	 	15	 

     

    

article
4 

 

License
Period

 

4.1             
License Grant and License Period. Upon Aptose’s payment of the Option Exercise Fee, the entirety of this Agreement
comes into effect for the duration of the License Period. During the License Period, Aptose will have the right to conduct clinical
studies to Develop and Commercialize Licensed Compounds and Products in accordance with this Article 4 (including the license granted
in Section 4.4) and Articles 5 (Development and Regulatory Activities) and 6 (Commercialization) below. The “License
Period” means the period of time commencing on the date Aptose pays the Option Exercise Fee to CG and ending upon
the expiration or termination of this Agreement pursuant to Article 12 (Term; Termination) below.

 

4.2             
Restrictions During License Period.

 

(a)              
 By CG. CG hereby covenants and agrees that, during the License Period, it shall not, and will ensure that its Affiliates
and licensees (other than Aptose) will not, either directly or indirectly, actively promote, market, distribute, import, sell or
have sold any Product into countries in the Licensed Territory. As to the countries in the Licensed Territory: (i) CG and its Affiliates
and licensees (other than Aptose) shall refrain from establishing or maintaining any branch, warehouse or distribution facility
for any Product in such countries; (ii) CG and its Affiliates and licensees (other than Aptose) shall not engage in any advertising
or promotional activities relating to any Product directed primarily to customers or other buyers or users of any Product located
in such countries; and (iii) CG and its Affiliates and licensees (other than Aptose) shall not solicit orders from any prospective
purchaser located in such countries. If CG or its Affiliates or licensees (other than Aptose) receives any order from a prospective
purchaser located in a country in the Licensed Territory, CG shall immediately refer that order to Aptose. CG and its Affiliates
and licensees (other than Aptose) shall not accept any such orders. CG and its Affiliates and licensees (other than Aptose) may
not deliver or tender (or cause to be delivered or tendered) any Product outside of the Retained Territory. CG shall not, and shall
ensure that its Affiliates and licensees will not, restrict or impede in any manner Aptose’s exercise of its rights in the
Licensed Territory.

 

(b)             
By Aptose. Aptose hereby covenants and agrees that, during the License Period, it shall not, and will ensure that its
Affiliates and Sublicensees will not, either directly or indirectly, actively promote, market, distribute, import, sell or have
sold any Product into countries in the Retained Territory. As to the countries in the Retained Territory: (i) Aptose and its Affiliates
and Sublicensees shall refrain from establishing or maintaining any branch, warehouse or distribution facility for any Product
in such countries; (ii) Aptose and its Affiliates and Sublicensees shall not engage in any advertising or promotional activities
relating to any Product directed primarily to customers or other buyers or users of any Product located in such countries; and
(iii) Aptose and its Affiliates and Sublicensees shall not solicit orders from any prospective purchaser located in such countries.
If Aptose or its Affiliates or Sublicensees receives any order from a prospective purchaser located in a country in the Retained
Territory, Aptose shall immediately refer that order to CG. Aptose and its Affiliates and Sublicensees shall not accept any such
orders. Aptose and its Affiliates and Sublicensees may not deliver or tender (or cause to be delivered or tendered) any Product
outside of the Licensed Territory. Aptose shall not, and shall ensure that its Affiliates and Sublicensees will not, restrict or
impede in any manner CG’s exercise of its rights in the Retained Territory.

    	 	16	 

     

    

4.3             
Right of First Refusal. The Parties acknowledge and agree that after the Option Period, CG’s obligations under
Section 3.7 (Exclusivity) above will expire, and CG shall thereafter be relieved of all restrictions concerning development and
commercialization of Competing Products and shall be free to, and regain the right to, research and develop Competing Products.
CG hereby grants to Aptose a right of first refusal, during the first two (2) years of the License Period, to obtain an exclusive
(even as to CG), worldwide license (with the right to grant sublicenses through multiple tiers) to research, develop, make, have
made, use, import, export, offer for sale, sell and otherwise commercialize Competing Products in the Field (“Aptose’s
Right of First Refusal”). Within five (5) days after the earlier of (a) CG’s receipt of an inquiry, unsolicited
offer or proposal from a Third Party with respect to a Competing Product, or (b) CG’s decision that it wishes to commence
discussions with a Third Party with respect to a Competing Product, CG shall notify Aptose in writing of such Competing Product
(the “CG Notice”) and shall provide Aptose with a reasonably detailed summary of all information in CG’s
possession or readily available to CG with regard to such Competing Product. Aptose shall have sixty (60) days after its receipt
of the CG Notice and related information to evaluate such information and to notify CG whether or not Aptose wishes to negotiate
with CG regarding rights to develop and commercialize such Competing Product. If Aptose so notifies CG of its exercise of Aptose’s
Right of First Refusal, then the Parties shall exclusively negotiate in good faith to seek to agree upon the terms and conditions
of an agreement under which CG would grant to Aptose exclusive licenses and other rights to develop and commercialize such Competing
Product. If Aptose does not notify CG of its interest in such Competing Product during such sixty (60)-day period, or if the Parties
do not enter into a written agreement governing such licenses and rights within one hundred eighty (180) days after CG’s
receipt of Aptose’s notice of its exercise of Aptose’s Right of First Refusal, or such longer period as may be agreed
by the Parties, then CG shall thereafter have the right to initiate or participate in discussions with Third Parties with respect
to the development and commercialization of such Competing Product; provided that CG shall not grant any Third Party any rights
to develop or commercialize the Competing Product on financial terms that are equally or more favorable to such Third Party than
the terms last offered by Aptose, where such “financial terms” are limited to only the upfront payments and development
milestone payments (which include all milestone payments based on events occurring prior to Regulatory Approval) without first
offering such Third Party terms to Aptose for a period of sixty (60) days. If Aptose notifies CG during such sixty (60)-day period
that it accepts such terms, then the Parties will thereafter negotiate and enter into an agreement granting Aptose the right to
develop and commercialize the Competing Product consistent with such terms. If Aptose does not notify CG that it accepts such terms
during such sixty (60)-day period, then CG may enter into an agreement with the applicable Third Party consistent with the terms
offered to Aptose; provided that if CG does not enter into such Third Party agreement with such Third Party, then this Section
4.3 will apply to any further offer from, or discussion or negotiation with, a Third Party with respect to the applicable (and
any other newly discovered) Competing Product.

    	 	17	 

     

    

4.4             
Commercial License Grant. Upon Aptose’s payment of the Option Exercise Fee, CG agrees to grant, and hereby grants,
Aptose an exclusive license (even as to CG), with the right to sublicense through multiple tiers in accordance with Section 4.5
(Sublicenses) below, under CG Intellectual Property for the Term of this Agreement to research, Develop, make, have made, use,
import, export, offer for sale, sell and otherwise Commercialize Licensed Compounds and Products in the Field in the Licensed Territory.
No additional license or rights are granted to Aptose other than as expressly set forth in this Agreement.

 

4.5             
Sublicenses. Aptose shall have the right to grant sublicenses through multiple tiers under any or all of the rights
granted in Section 4.4 (Commercial License Grant) to its Affiliates and to Third Parties; provided that each such sublicense shall
be consistent with the terms and conditions of this Agreement. Aptose will promptly provide CG with the name and address of any
of its Sublicensees. Any sublicense will not relieve Aptose of its obligations to CG under this Agreement. Aptose will be responsible
for all obligations under this Agreement applicable to any such Sublicensee, and will remain fully responsible for performance
of this Agreement notwithstanding any sublicenses granted.

 

4.6             
CG’s Retained Rights. CG retains all rights not expressly granted to Aptose hereunder including but not limited
to the right under CG Intellectual Property to research, Develop, make, have made, use, import, export, offer for sale, sell and
otherwise Commercialize Licensed Compounds and Products in the Field in the Retained Territory.

 

article
5 

 

Development
and Regulatory Activities

 

5.1             
Development of Licensed Compounds and Products. As between the Parties, Aptose shall have sole control, authority and
discretion, at its sole expense, over the research and Development of Licensed Compounds and Products in the Field in the Licensed
Territory, including all regulatory activities related thereto, as further described in this Article 5. Except as provided in Section
5.5 (Clinical Development in Retained Territory) below, CG shall be solely responsible for, at its sole expense, Development of
Licensed Compounds and Products in the Field in the Retained Territory.

 

5.2             
Committees.

 

(a)              
Advisory Committee.

    	 	18	 

     

    

(i)                
Establishment. The Parties hereby establish an Advisory Committee (the “Advisory Committee”),
to discuss the Development Plan, including amendments thereto, and strategies for research and Development of Licensed Compounds
and Products during the Option Period. The Advisory Committee will be composed of three (3) senior personnel of each Party, each
of whom shall have experience in pharmaceutical discovery and development. Within thirty (30) days after the commencement of the
Option Period, each Party will designate its initial members to serve on the Advisory Committee and notify the other Party of the
dates of availability for the first meeting of the Advisory Committee. Each Party may replace its representatives on the Advisory
Committee on written notice to the other Party.

 

(ii)             
Meetings. The Advisory Committee shall meet semiannually during the Option Period, and will thereafter disband and be
replaced by the Partnership Review Committee. The first meeting of the Advisory Committee shall be held as soon as reasonably practicable,
but in no event later than sixty (60) days, following the Effective Date. Meetings shall be held at such place or places as are
mutually agreed or by teleconference or videoconference. Each Party may from time to time invite a reasonable number of participants
who are under obligations of confidentiality consistent with this Agreement, in addition to its representatives, to attend Advisory
Committee meetings in a non-voting capacity, with the consent of the other Party (which shall not be unreasonably withheld). At
each meeting of the Advisory Committee, Aptose will update CG on, and the Parties will review and discuss, the Development
Plan and the status of Aptose’s Development activities with respect to Licensed Compounds and Products in the Licensed Territory,
and Aptose will provide CG with semiannual updates summarizing its plans for and progress with respect to Development of Products
in the Licensed Territory. Each Party shall solely bear all costs it incurs in connection with its participation at any meetings
under this Section.

 

(b)             
Partnership Review Committee.

 

(i)                
Establishment. Promptly after the commencement of the License Period, the Parties will establish a Partnership Review
Committee (the “Partnership Review Committee”), to discuss the Development Plan, including amendments
thereto, and strategies for Development of Licensed Compounds and Products. The Partnership Review Committee will be composed of
three (3) senior personnel of each Party, each of whom shall have experience in pharmaceutical discovery and development. Within
thirty (30) days after the commencement of the License Period, each Party will designate its initial members to serve on the Partnership
Review Committee and notify the other Party of the dates of availability for the first meeting of the Partnership Review Committee.
Each Party may replace its representatives on the Partnership Review Committee on written notice to the other Party. The activities
of the Partnership Review Committee as set forth in Section 5.2(b)(ii) below shall continue until the first Regulatory Approval
for a Product in the Licensed Territory, at which point the Partnership Review Committee will disband.

 

(ii)             
Meetings. The Partnership Review Committee shall meet at least once per year until disbanded. The first meeting of the
Partnership Review Committee shall be held as soon as reasonably practicable, but in no event later than sixty (60) days, following
the commencement of the License Period. Meetings shall be held at such place or places as are mutually agreed or by teleconference
or videoconference. Each Party may from time to time invite a reasonable number of participants who are under obligations of confidentiality
consistent with this Agreement, in addition to its representatives, to attend Partnership Review Committee meetings in a non-voting
capacity, with the consent of the other Party (which shall not be unreasonably withheld). At each meeting of the Partnership Review
Committee, Aptose will update CG on, and the Parties will review and discuss, the Development Plan and the status of Aptose’s
Development activities with respect to Licensed Compounds and Products in the Licensed Territory, and until First Commercial Sale
of a Product in the Licensed Territory, Aptose will provide CG with annual updates summarizing its plans for and progress with
respect to Development of Products in the Licensed Territory. Each Party shall solely bear all costs it incurs in connection with
its participation at any meetings under this Section.

    	 	19	 

     

    

(c)              
Advisory Only. For clarity, the roles of the Advisory Committee and Partnership Review Committee are advisory only.
Aptose retains all decision-making rights regarding the Development of Licensed Compounds and Products in the Licensed Territory.
Subject to Section 5.5, CG retains all decision-making rights regarding the Development of Licensed Compounds and Products in the
Retained Territory.

 

5.3             
Development Plan. Within one hundred eighty (180) days after the beginning of the Option Period, Aptose shall prepare
and provide to the Advisory Committee a draft development plan for development of Products in the Field in the Licensed Territory
for the subsequent twelve (12)-month period, and shall consider in good faith all reasonable comments provided by the Advisory
Committee before preparing a final version of such plan (as updated from time to time in accordance with this Section, the “Development
Plan”). The Development Plan may be supplemented, modified and updated by Aptose from time to time, and, until the
Partnership Review Committee disbands, Aptose shall provide each such updated Development Plan to the Advisory Committee or Partnership
Review Committee for review and discussion.

 

5.4             
CG Development Activities. Subject to Section 5.5, CG will retain the exclusive right to, and be solely responsible
for all aspects of, Development and Commercialization of Licensed Compounds and Products in the Field in the Retained Territory
at its sole expense. Additionally, upon Aptose’s request, and as mutually agreed by the Parties, CG may elect to conduct
certain Development activities for Licensed Compounds or Products in the Field in the Licensed Territory. If the Parties agree
that CG will conduct any such Development activities, they will prepare a detailed description, timeline and budget for all such
activities, and upon mutual written agreement thereof, Aptose will update the Development Plan to include such activities. CG shall
conduct any such Development activities for the Licensed Compounds and Products in the Field in accordance with the Development
Plan and all Applicable Laws and under the direction of Aptose. Aptose shall reimburse CG for its fully burdened costs for such
development activities in accordance with the mutually agreed-upon Development Plan and budget contained therein. CG shall provide
Aptose with detailed invoices for such costs and adequate supporting documentation for such invoices. In connection with such activities,
CG shall maintain complete, current and accurate records of all such Development activities conducted by it, and all Information
resulting from such activities, which records shall fully and properly reflect all work done and results achieved in the performance
of such Development activities in good scientific manner appropriate for regulatory and patent purposes.

 

5.5             
Clinical Development in Retained Territory. 

    	 	20	 

     

    

(a)              
Clinical Trials. CG shall keep Aptose updated on the status of the Development of Licensed Compounds and Products in
the Retained Territory, including any communications with Regulatory Authorities in the Retained Territory about clinical trials
of a Product that are required to obtain Regulatory Approval of such Product in the Retained Territory. If any such clinical trials
are required, or if CG otherwise desires to conduct any clinical trials of a Product in the Retained Territory, CG shall promptly
notify Aptose and provide its proposed development plan, including protocols for all clinical trials, and Aptose shall have the
right, but no obligation, to design and oversee such clinical trials in the Retained Territory, in accordance with any recommendations
or requirements by the applicable Regulatory Authorities in the Retained Territory.

 

(b)             
Aptose Design of Trials. If following receipt of CG’s notice under Section 5.5(a), Aptose notifies CG that it
elects to design and oversee such clinical trials, Aptose shall revise the development plan provided by CG, including clinical
trial design and protocols for such clinical trials, which plan will be implemented by a Third Party and/or by CG, as agreed by
the Parties in writing. CG shall conduct, or shall ensure that its Affiliate and Third Party contractor conduct, all Development,
including clinical trials, of Licensed Compounds and Products in accordance with the development plan prepared by Aptose and agreed
upon by the Parties in writing and in accordance with all Applicable Laws.

 

(c)              
CG Design of Trials. If Aptose does not notify CG that it elects to design and oversee such clinical trials, then CG
shall have the right to do so, provided that CG shall provide its development plan, including clinical trial design and protocols,
to Aptose for review and comment and shall consider all comments provided by Aptose in good faith before finalizing such plan.
If Aptose does not approve of CG’s final development plan, then Aptose may exercise its rights under Section 5.5(b), and
CG shall not conduct the applicable clinical trials under the development plan that was not approved by Aptose; provided that if
Aptose does not exercise its rights under Section 5.5(b), CG may proceed with its plan.

 

(d)             
Regulatory Activities. CG, itself or through its Affiliate or licensee, shall be solely responsible for all communications
with Regulatory Authorities in connection with all clinical trials in the Retained Territory, whether coordinated with the trials
of Aptose or by CG, and CG will be the regulatory sponsor for such clinical trials. CG shall keep Aptose regularly updated on the
progress of all clinical trials in the Retained Territory, including by timely providing all Information required under Section
3.5 (Technology Transfer and Access to Data).

 

(e)              
Supply of Products. CG shall purchase all of its and its Affiliates’ and licensees’ requirements for Licensed
Compounds for clinical trials in the Retained Territory from Aptose or its Third Party contract manufacturer, at a price equal
to Aptose’s fully-burdened manufacturing cost plus a markup of fifteen percent (15%) thereof. CG shall not purchase any Licensed
Compound for commercial use in the Retained Territory from a Third Party without Aptose’s written approval thereof, based
on a quality audit (including for quality accreditation and GMP compliance) conducted by or on behalf of Aptose, which approval
shall not be unreasonably withheld.

 

(f)               
Costs. CG shall be solely responsible for all costs incurred to conduct all Development, including clinical trials,
of Products in the Retained Territory, and shall reimburse all out-of-pocket expenses incurred by Aptose in connection with coordinating
activities under this Section 5.5, within thirty (30) days after receipt of an invoice from Aptose for such costs. Aptose shall
provide CG with detailed invoices for such costs and adequate supporting documentation for such invoices. In connection with such
activities, Aptose shall maintain complete, current and accurate records of all such Development activities conducted by it, and
all Information resulting from such activities, which records shall fully and properly reflect all work done and results achieved
in the performance of such Development activities in good scientific manner appropriate for regulatory and patent purposes

    	 	21	 

     

    

5.6             
Conduct of Development Activities; Diligence. Aptose shall conduct all Development of Licensed Compounds and Products
in the Field in the Licensed Territory in accordance with the then-current Development Plan and in compliance with all Applicable
Laws. Following Aptose’s exercise of the Option, Aptose shall use Commercially Reasonable Efforts to Develop at least one
Product in the Licensed Territory, alone or with or through one (1) or more Affiliates or Sublicensees; provided, however, if Aptose
fails to conduct any meaningful development activities for the Licensed Compounds and Products over a period of six (6) continuous
months, then such failure shall be deemed to be a failure to meet the diligence obligations set forth in this Section and a material
breach of a material provision of this Agreement, and CG shall have the right to terminate this Agreement in accordance with Section
12.3 (Termination by Either Party for Material Breach) below. Meaningful development activities include, without limitation, (a)
planning, preparing for the conduct of (including drafting protocols and negotiating with clinical research organization and clinical
trial sites) and writing study reports for clinical trials and (b) conducting regulatory affairs, including planning for and attending
regulatory meetings, preparing Regulatory Filings and addressing issues raised by Regulatory Authorities; provided, however, if
Aptose has failed to submit to or discuss with a Regulatory Authority a Regulatory Filing that includes Aptose’s proposed
protocol for the then subsequent clinical trial within twelve (12) months after the last patient out of each Phase 1 Clinical Trial
and Phase 2 Clinical Trial (excluding a Phase 2 Clinical Trial that is a Pivotal Clinical Trial or that is otherwise the final
clinical trial before submission of an MAA for a Product) conducted by Aptose, then Aptose shall be deemed to be in material breach
of its diligence obligations hereunder, and CG shall have the right to terminate this Agreement in accordance with Section 12.3
(Termination by Either Party for Material Breach) below; provided that such twelve (12)-month period will be extended automatically
by the amount of any delay resulting from (i) clinical or regulatory delays that are outside of Aptose’s reasonable control,
including requests or requirements of a Regulatory Authority beyond what would be reasonably anticipated, or (ii) delays in manufacturing
needed quantities of Licensed Compounds or Products that are outside of Aptose’s reasonable control.

 

5.7             
Regulatory Approvals. As between the Parties, Aptose shall be solely responsible for and shall bear the entire cost
of preparing and submitting all Regulatory Filings for Products in the Field in the Licensed Territory. As between the Parties,
all Regulatory Approvals for Products in the Licensed Territory shall be held by and in the name of Aptose, and Aptose shall own
all Regulatory Filings in connection therewith; provided, however, if CG terminates this Agreement in accordance with Section 12.3
(Termination by Either Party for Material Breach) due to a material breach by Aptose, then Aptose will transfer and assign all
Regulatory Approvals for Products in the Licensed Territory to CG in accordance with Section 12.4(f) (Results of Termination).

    	 	22	 

     

    

5.8             
Use of Subcontractors. Aptose may perform its research and Development activities under this Agreement through one or
more subcontractors, provided that Aptose will remain responsible for the work allocated to, and payment to, such subcontractors
to the same extent it would if it had done such work itself.

 

5.9             
Access to Data. Each Party acknowledges and agrees that once Aptose pays the Option Exercise Fee:

 

(a)              
By CG. At least annually during the License Period pursuant
to Section 5.2(b), CG shall provide to Aptose or its designee all CG Know-How, including CG Data, generated since the last such
disclosure (if any) that is necessary or useful for Aptose to exercise the licenses granted in Sections 4.1 and 4.4 above. During
the License Period, CG shall furnish Aptose with electronic copies of, and if reasonably requested by Aptose, physical access to
the originals of, any and all documents, electronic records, databases and other tangible materials included in the CG Know-How.
As reasonably requested by Aptose, during the License Period, CG shall provide, at no additional cost to Aptose, reasonable technical
support (by teleconference, by electronic means or in-person at CG’s or its contractor’s facilities during regular
business hours and upon reasonable advance notice, as needed) to support such technology transfer. In addition, upon Aptose’s
request, CG will provide to Aptose a reasonable amount of an appropriate internal standard for research purposes, and Aptose will
reimburse CG for its reasonable costs to provide such supply. Aptose shall have the right to incorporate CG Data in
any Regulatory Filings with Regulatory Authorities for a Product in the Licensed Territory and to cross-reference Regulatory Filings
Controlled by CG in the Retained Territory, in each case for the purpose of obtaining and maintaining Regulatory Approval for Products
in the Field in the Licensed Territory, and otherwise exercising its rights or fulfilling its obligations under this Agreement.

 

(b)             
By Aptose. On an
annual basis after the commencement of the License Period pursuant to Section 5.2(b), Aptose shall provide CG with copies of or
access to all Aptose Data not previously provided to CG. CG shall have the right to use Aptose Data as necessary to seek to obtain
and maintain Regulatory Approval for Products in the Retained Territory, including the right to incorporate Aptose Data
in Regulatory Filings with Regulatory Authorities in the Retained Territory and to cross-reference Regulatory Filings Controlled
by Aptose in the Licensed Territory, in each case for the purpose of obtaining and maintaining Regulatory Approval for Products
in the Retained Territory, and otherwise to exercise its rights or fulfill
its obligations under this Agreement.

 

5.10         
Access to Sublicensee Data. In the event that Aptose enters into an agreement with a Sublicensee in accordance with
Section 4.5 (Sublicenses) above, if such Sublicensee is involved in generation of Data, Aptose shall use commercially reasonable
efforts to require that such Sublicensee allow Aptose to provide CG access to and the right to use all such Data generated by such
Sublicensee, to the extent that such Data is reasonably necessary or useful for Development or Commercialization of Licensed Compounds
and Products in the Field in the Retained Territory, including preparation and filing of MAAs for a Product with the applicable
Regulatory Authorities in the Retained Territory, in accordance with this Agreement; provided that Aptose shall require each Sublicensee
to allow Aptose to provide to CG access and the right to use all Data related to Licensed Compounds and Products that is (i) Safety
Data or (ii) otherwise necessary to be provided to any Regulatory Authority in the Retained Territory in connection with the Development
and Commercialization of Licensed Compounds and Products in the Field in the Retained Territory. CG shall ensure that each of its
Affiliates and licensees allows CG to provide Aptose access to and the right to use all Data generated by such Affiliate or licensee,
and Aptose shall have the right to use such Data to the extent permitted under this Agreement, including the right to incorporate
all Data into any Regulatory Filings for a Product in the Licensed Territory.

    	 	23	 

     

    

5.11         
Materials Transfer. In order to facilitate the Development activities contemplated by this Agreement, either Party may
provide to the other Party certain biological materials or chemical compounds Controlled by the supplying Party (collectively,
“Materials”) for use by the other Party in furtherance of such Development activities. Except as otherwise
provided for under this Agreement, all such Materials delivered to the other Party will remain the sole property of the supplying
Party, will be used only in furtherance of the Development activities conducted in accordance with this Agreement, will not be
used or delivered to or for the benefit of any Third Party, except for subcontractors, without the prior written consent of the
supplying Party, and will be used in compliance with all Applicable Laws. The Materials supplied under this Agreement must be used
with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. Except as
expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY,
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE
OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD
PARTY.

 

5.12         
Regulatory Activities.

 

(a)              
CG’s Obligations. CG agrees to keep Aptose informed of the preparation, Regulatory Authority review and approval
of submissions and communications with Regulatory Authorities with respect to Products in the Field in the Retained Territory.
Accordingly, at each regularly scheduled Advisory Committee or Partnership Review Committee meeting, as applicable, CG shall provide
Aptose with copies of all material documents, information and correspondence received from a Regulatory Authority relating to Licensed
Compounds or Products in the Retained Territory.

 

(b)             
Aptose’s Obligations. Aptose agrees to keep CG informed of the preparation, Regulatory Authority review and approval
of submissions and communications with Regulatory Authorities with respect to Products in the Field in the Licensed Territory.
Accordingly, at each regularly scheduled Partnership Review Committee meeting, Aptose shall provide CG with copies of all material
documents, information and correspondence received from a Regulatory Authority relating to Licensed Compounds or Products in the
Licensed Territory.

 

5.13         
Adverse Event Reporting; Pharmacovigilance Agreement. As between the Parties: (a) Aptose shall be responsible for
the timely reporting of all relevant adverse drug reactions/experiences, Product quality, Product complaints and Safety Data relating
to Licensed Compounds and Products to the appropriate Regulatory Authorities in the Licensed Territory; and (b) CG shall be responsible
for the timely reporting of all relevant adverse drug reactions/experiences, Product quality, Product complaints and Safety Data
relating to Licensed Compounds and Products to the appropriate Regulatory Authorities in the Retained Territory, in each case in
accordance with Applicable Laws of the relevant countries and Regulatory Authorities. The Parties shall cooperate with each other
with respect to their respective pharmacovigilance responsibilities, and each Party shall be solely responsible for costs relating
to its respective pharmacovigilance responsibilities, unless agreed otherwise by the Parties in writing. Prior to Aptose’s
first filing of an IND for a Product, the Parties shall enter into a pharmacovigilance agreement on terms that comply with ICH
guidelines, including: (i) providing detailed procedures regarding the maintenance of core safety information and the exchange
of Safety Data relating to Licensed Compounds and Products worldwide within appropriate timeframes and in an appropriate format
to enable each Party to meet both expedited and periodic regulatory reporting requirements; (ii) ensuring compliance with
the reporting requirements of all applicable Regulatory Authorities on a worldwide basis for the reporting of Safety Data in accordance
with standards stipulated in the ICH guidelines, and all applicable regulatory and legal requirements regarding the management
of Safety Data; and (iii) providing for a global safety database to be established and maintained by Aptose at its cost.

    	 	24	 

     

    

article
6

 

Commercialization

 

6.1             
Commercialization Responsibilities. Aptose will have the exclusive right to conduct, and be solely responsible for all
aspects of, the Commercialization of Products in the Field in the Licensed Territory, including: (a) developing and executing a
commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities regarding the price and reimbursement
status of Products; (c) marketing and promotion; (d) booking sales and distribution and performance of related services; (e) handling
all aspects of order processing, invoicing and collection, inventory and receivables; (f) providing customer support, including
handling medical queries, and performing other related functions; (g) conforming its practices and procedures to Applicable Laws
relating to the marketing, detailing and promotion of Products in the Licensed Territory; and (h) manufacturing of Products for
commercial use. As between the Parties, Aptose shall bear all of its costs and expenses incurred in connection with such Commercialization
activities.

 

6.2             
Commercial Diligence. Aptose shall use Commercially Reasonable Efforts to Commercialize in the Field in the Licensed
Territory at least one Product for which it has obtained Regulatory Approval. Material failure to meet the diligence obligations
set forth in this Section shall be deemed a material breach of a material provision of this Agreement, and CG shall have the right
to terminate this Agreement in accordance with Section 12.3 (Termination by Either Party for Material Breach) below.

 

6.3             
Commercialization Reports. On an annual basis, after the First Commercial Sale of a Product anywhere in the Licensed
Territory, Aptose shall provide CG with a summary of Aptose’s significant Commercialization activities with respect to each
Product in the Licensed Territory since the last such report.

    	 	25	 

     

    

6.4             
Use of Subcontractors. Aptose may perform its Commercialization activities under this Agreement through one or more
subcontractors, provided that Aptose will remain responsible for the work allocated to, and payment to, such subcontractors to
the same extent it would if it had done such work itself.

 

article
7

 

Financial Terms

 

7.1             
Milestone Payments.

 

(a)              
Development Milestones. Aptose shall notify CG within thirty (30) days after the first achievement by Aptose or its
Affiliates or Sublicensees of the following development milestone events. Thereafter, CG shall invoice Aptose for the corresponding
milestone payment, and Aptose shall pay each such invoice within forty-five (45) days after receipt thereof.

 

	Development Milestone Event	Milestone Payment (in Dollars)
	Initiation of the first Phase 2 Clinical Trial of a Product	$6 million
	Initiation of the first Pivotal Clinical Trial of a Product	$10 million

 

Each of the above milestone
payments is payable one time only, regardless of the number of times the corresponding event is achieved by a Product and regardless
of the number of Products to achieve such event. For clarity, the above milestone payments shall be paid only for the first Product.
Under no circumstances shall Aptose be obligated to pay CG more than sixteen million Dollars ($16,000,000) pursuant to this Section
7.1(a).

 

(b)             
Regulatory Milestones. Aptose shall notify CG within thirty (30) days after the first achievement by Aptose or its Affiliates
or Sublicensees of the following regulatory milestone events by each Product. Thereafter, CG shall invoice Aptose for the corresponding
milestone payment, and Aptose shall pay each such invoice within forty-five (45) days after receipt thereof.

 

	Regulatory Milestone Event	Milestone Payment (in Dollars) (per Product)
	Acceptance for filing by the FDA of the first NDA for a Product	$7 million
	Acceptance for filing by the EMA of the first MAA for a Product	$7 million
	Acceptance for filing by the MHLW of the first MAA for a Product	$4 million
	First Regulatory Approval of a Product by the FDA	$10 million
	Earlier of (a) first Regulatory Approval of a Product by the EMA by the centralized procedure (including Pricing Approvals reasonably acceptable to Aptose in at least three (3) Major European Countries) or (b) first Regulatory Approval of a Product in at least three (3) Major European Countries	$10 million
	First Regulatory Approval of a Product by the MHLW	$6 million

 

    	 	26	 

     

    

Each of the above milestone
payments is payable one time per Product, regardless of the number of times the corresponding event is achieved by such Product,
except that each milestone payment for a Regulatory Approval event is payable up to five times as follows for each Product: at
100% of the amount set forth above for the first Indication, at 100% of the amount set forth above for up to two (2) additional
non-oncology Indications and at 50% of the amount set forth above for up to two (2) additional oncology Indications. All formulations
containing the same Licensed Compound will be considered the same Product for purposes of this Section 7.1(b). For example, if
Aptose develops a tablet formulation comprising CG’806 and pays the applicable regulatory milestone payments for such tablet
formulation as set forth above, and later develops an injectable formulation comprising CG’806, the achievement of the regulatory
milestones by the injectable formulation will not trigger another payment of the applicable regulatory milestone payment. Under
no circumstances shall Aptose be obligated to pay CG more than one hundred twenty-two million Dollars ($122,000,000) per Product
pursuant to this Section 7.1(b).

 

(c)              
Sales Milestones. Aptose shall notify CG within sixty (60) days after the end of the calendar year in which the aggregate
annual Net Sales of each Product by Aptose and its Affiliates and Sublicensees in the Licensed Territory first reach each of the
amounts specified below. Thereafter, CG shall invoice Aptose for the corresponding milestone payment, and Aptose shall pay each
such invoice within forty-five (45) days after receipt thereof. For clarity, the milestone payments in this Section 7.1(c) shall
be additive such that if two or more milestones below are achieved in the same calendar year, Aptose shall pay all applicable payments
to CG for that calendar year.

 

	Sales Milestone Event	Milestone Payment (in Dollars) (per Product)
	The aggregate Net Sales of a Product in the Licensed Territory in a calendar year exceed seven hundred fifty million Dollars ($750,000,000)	Fifteen million Dollars ($15,000,000)
	The aggregate Net Sales of a Product in the Licensed Territory in a calendar year exceed one billion Dollars ($1,000,000,000)	Twenty-five million Dollars ($25,000,000)
	The aggregate Net Sales of a Product in the Licensed Territory in a calendar year exceed five billion Dollars ($5,000,000,000)	One hundred twenty-two million Dollars ($122,000,000)

 

    	 	27	 

     

    

Each of the above milestone
payments is payable one time per Product, regardless of the number of times the corresponding event is achieved by such Product.
All formulations containing the same Licensed Compound will be considered the same Product for purposes of this Section 7.1(c).
For example, if Aptose develops a tablet formulation comprising CG’806 and pays the applicable sales milestone payments for
such tablet formulation as set forth above, and later develops an injectable formulation comprising CG’806, the achievement
of the sales milestones by the injectable formulation will not trigger another payment of the applicable sales milestone payment.
Under no circumstances shall Aptose be obligated to pay CG more than one hundred sixty-two million Dollars ($162,000,000) per Product
pursuant to this Section 7.1(c).

 

7.2             
Royalties.

 

(a)              
Royalty Rates. Subject to Sections 7.2(c)-(e), Aptose shall pay to CG royalties equal to four percent (4%) of aggregate
annual Net Sales of all Products in the Field in the Licensed Territory during the applicable Royalty Term.

 

(b)             
Royalty Term. Royalties shall be paid under this Section 7.2, on a country-by-country and Product-by-Product basis,
on Net Sales during the period of time beginning on the First Commercial Sale of such Product in such country and continuing until
the later of: (i) the expiration of the last-to-expire Valid Claim of the CG Patents in such country Covering such Product; and
(ii) ten (10) years after the First Commercial Sale of such Product in such country (the “Royalty Term”).

 

(c)              
Know-How Reduction. If, during the Royalty Term for a Product and country, there is no Valid Claim of a CG Patent in
such country Covering such Product, Aptose shall pay royalties on Net Sales of such Product in such country at a rate of two percent
(2%) of Net Sales of such Product in such country.

 

(d)             
Generic Entry. Subject to Aptose’s obligations in Section 8.3(b) (Patent Enforcement) below, if a Generic Product
to any Product is sold in a country in the Licensed Territory during any calendar quarter in the Royalty Term for such Product
and country, then royalties as set forth in this Section 7.2 would be subject, on a country-by-country and product-by-product basis
to reduction for generic entry as follows: if the total sales volumes of Generic Product during two consecutive quarters exceeds
twenty-five percent (25%) of the combined total sales volume of Product and Generic Product, then the royalty rate shall be reduced
by fifty percent (50%).

    	 	28	 

     

    

(e)              
Deduction for Third Party Patents or Information. Aptose shall have the right to deduct from royalties payable to CG
under this Section 7.2 up to fifty percent (50%) of any amounts paid by Aptose to a Third Party in consideration for the grant
of a license to Aptose under any Patents or Information of such Third Party that are necessary to practice any of the CG Intellectual
Property; provided that in no event shall the deductions under this Section 7.2(e) reduce royalties due to CG in any calendar
quarter to less than fifty percent (50%) of the amount that would otherwise be due to CG under this Section 7.2. Aptose may carry
forward to subsequent calendar quarters any amounts it could not deduct as a result of the foregoing proviso.

 

7.3             
Royalty Reports and Payments. Within sixty (60) days after the end of each calendar quarter during the Royalty Term,
Aptose shall deliver to CG a statement, on a country-by-country and Product-by-Product basis, of the amount of gross sales and
Net Sales of Products during the applicable calendar quarter, a calculation of the amount of the royalty payment due on such sales
for such calendar quarter, any applicable deductions under Section 7.2(e) and a calculation of the payment due after the application
of such deductions. Aptose shall include with each such report the payment of the royalties due for such calendar quarter.

 

7.4             
Foreign Exchange. The rate of exchange to be used in computing the amount of currency equivalent in Dollars of Net Sales
invoiced in other currencies shall be the rate used by Aptose in its financial reporting in accordance with International Financial
Reporting Standards.

 

7.5             
Manner and Place of Payment. All payments owed by Aptose under this Agreement shall be made in Dollars by wire transfer
in immediately available funds to a bank and account designated in writing by CG.

 

7.6             
Records; Audits. Aptose and its Affiliates and Sublicensees will maintain complete and accurate records in reasonably
sufficient detail to permit CG to confirm the accuracy of the calculation of royalty payments and the achievement of sales milestone
events, and any amounts invoiced under Section 5.5(e). CG and its Affiliates will maintain complete and accurate records in reasonably
sufficient detail to permit Aptose to confirm the accuracy of the amounts invoiced under Section 5.4. Upon reasonable prior notice,
such records shall be available during regular business hours for a period of three (3) years from the end of the calendar year
to which they pertain for examination, not more often than once each calendar year, by an independent certified public accountant
selected by the auditing Party and reasonably acceptable to the audited Party, for the sole purpose of verifying the accuracy of
the financial reports furnished by the other Party pursuant to this Agreement. Any such auditor shall enter into a confidentiality
agreement with the audited Party and shall not disclose the audited Party’s Confidential Information, except to the extent
such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments
due by one Party to the other Party under this Agreement. Any amounts shown to be owed but unpaid shall be paid, and any amounts
showed to be overpaid will be refunded, within forty-five (45) days from the accountant’s report. The auditing Party shall
bear the full cost of such audit unless such audit discloses an underpayment or overcharge by the audited Party of more than ten
percent (10%) of the amount due, in which case the audited Party shall bear the full cost of such audit.

    	 	29	 

     

    

7.7             
Taxes.

 

(a)              
Taxes on Income. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income
arising directly or indirectly from the efforts of the Parties under this Agreement.

 

(b)             
Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax
withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Aptose to CG under this
Agreement. To the extent Aptose is required to deduct and withhold taxes on any payment to CG, Aptose shall pay the amounts of
such taxes to the proper Governmental Authority in a timely manner and promptly transmit to CG an official tax certificate or other
evidence of such withholding sufficient to enable CG to claim such payment of taxes. CG shall provide Aptose any tax forms that
may be reasonably necessary in order for Aptose not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral
income tax treaty. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable
Laws, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery
to be for the benefit of the Party bearing such withholding tax or value added tax.

 

article
8 

 

Intellectual
Property

 

8.1             
Data and Inventions.

 

(a)              
Aptose Program Technology. As between the Parties, Aptose shall own the entire right, title and interest in and to any
and all Information, including Data, discovered, generated, created or made (i) by it and its Affiliates and their respective employees,
agents or independent contractors in the course of performing or exercising Aptose’s rights under this Agreement, or (ii)
by CG and its Affiliates and their respective employees, agents or independent contractors in connection with or as a result of
CG’s work conducted in response to Aptose’s request to conduct certain Development activities for Licensed Compounds
or Products in the Field in the Licensed Territory as set forth in Section 5.4, and all intellectual property rights in any of
the foregoing (collectively, the “Aptose Program Technology”). Aptose hereby grants to CG a co-exclusive
license (with Aptose), with the right to sublicense through multiple tiers, under the Aptose Program Technology for the Term of
this Agreement to research, Develop, make, have made, use, import, export, offer for sale, sell and otherwise Commercialize Licensed
Compounds and Products in the Field in the Retained Territory.

 

(b)             
Joint Technology.  The Parties shall own jointly any and all Information, including Data, discovered, generated, created
or made jointly by two or more individual inventors with at least one individual inventor being an employee or consultant to each
of the Parties and/or its respective Affiliates and/or their respective approved subcontractors in the course of performing or
exercising the Parties’ rights under this Agreement, together with all Patents and other intellectual property rights in
any such jointly made Information, but excluding the Aptose Program Technology (collectively, the “Joint Technology”).
Each Party may exercise its ownership rights in and to such Joint Technology, including the right to license or otherwise to exploit,
transfer or encumber its ownership interest, without an accounting or obligation to, or consent required from, the other Party,
but subject to the obligations under this Agreement and any licenses granted under or in accordance with this Agreement.

    	 	30	 

     

    

(c)              
Personnel Obligations. Each Party shall ensure that each employee, agent or independent contractor of a Party or its
respective Affiliates or Sublicensees performing work under this Agreement is, prior to commencing such work, bound by invention
assignment obligations, including: (i) promptly reporting any invention, discovery, process or other intellectual property; (ii)
presently assigning to the applicable Party or Affiliate all of his or her right, title and interest in and to any invention, discovery,
process or other intellectual property; (iii) cooperating in the preparation, filing, prosecution, maintenance and enforcement
of any patent and patent application; and (iv) performing all acts and signing, executing, acknowledging and delivering any and
all documents required for effecting the obligations and purposes of this Agreement. It is understood and agreed that such invention
assignment agreement need not reference or be specific to this Agreement.

 

8.2             
Patent Prosecution.

 

(a)              
Filing, Prosecution and Maintenance of CG Patents in the Licensed Territory.

 

(i)                
As between the Parties, Aptose will have the first right to file, prosecute and maintain the CG Patents in the Licensed
Territory at its own expense, through patent counsel of its choice. Aptose may exercise any of its rights under this Section 8.2
through an Affiliate or Sublicensee.

 

(ii)             
Promptly after the Effective Date, CG shall (A) transfer the existing, complete patent files for all CG Patents in the
Licensed Territory to Aptose and communicate to Aptose all facts and information then known to CG comprising or relating thereto,
(B) furnish Aptose with copies of, and if reasonably requested by Aptose, physical access to the originals of, any and all documents,
electronic records, samples and other tangible materials in CG’s Control that relate directly to the CG Patents in the Licensed
Territory and/or that may be useful for the exercise of Aptose’s rights under this Section 8.2, and (C) file all documents
necessary to transfer correspondence with the U.S. Patent and Trademark Office and other applicable patent authorities to Aptose
and shall give Aptose’s patent counsel power of attorney thereto. CG shall cooperate with Aptose in the transfer of all prosecution
and maintenance responsibilities relating to the CG Patents in the Licensed Territory. CG shall keep Aptose reasonably informed
of all inventions made after the Effective Date and patent applications filed after the Effective Date in the Retained Territory,
in each case that could form the basis for a CG Patent. CG shall provide Aptose, at Aptose’s request and expense, with any
assistance reasonably requested by Aptose with respect to the filing, prosecution or maintenance of the CG Patents in the Licensed
Territory.

 

(iii)           
CG shall (A) notify Aptose in writing with respect to all significant developments regarding the CG Patents in the Retained
Territory, (B) promptly provide Aptose with a copy of each material communication from any patent authority regarding the CG Patents
in the Retained Territory, and (C) provide Aptose with drafts of each material filing (including draft patent applications and
responses to office actions and similar filings) with respect to the CG Patents in the Retained Territory a reasonable amount of
time in advance of the anticipated filing date and shall consider Aptose’s reasonable comments thereto in good faith. CG
shall not undertake any patent prosecution or enforcement action in the Retained Territory that Aptose deems to be detrimental
to the prosecution or enforcement of the CG Patents in the Licensed Territory.

    	 	31	 

     

    

(iv)            
Aptose shall (A) notify CG in writing with respect to all significant developments regarding the CG Patents in the Licensed
Territory, (B) promptly provide CG with a copy of each material communication from any patent authority regarding the CG Patents
in the Licensed Territory, and (C) provide CG with drafts of each material filing (including draft patent applications and responses
to office actions and similar filings) with respect to the CG Patents a reasonable amount of time in advance of the anticipated
filing date and shall consider CG’s reasonable comments thereto in good faith.

 

(v)              
Aptose shall notify CG of any decision to cease prosecution and/or maintenance of any CG Patent in any country in the
Licensed Territory. Aptose shall, to the extent practicable, provide such notice at least thirty (30) days prior to any filing
or payment due date, or any other due date that requires action in order to avoid loss of rights, in connection with such CG Patent.
In such event, Aptose shall permit CG, at its discretion and expense, to continue prosecution or maintenance of such CG Patent
in such country, and Aptose shall take all steps required to enable CG to take over prosecution and maintenance and otherwise give
full effect to the foregoing. CG’s prosecution or maintenance of such CG Patent shall not change the Parties’ respective
rights and obligations under this Agreement with respect to such CG Patent other than those expressly set forth in this Section
8.2(a)(iv).

 

(b)             
Filing, Prosecution and Maintenance of Patents in Aptose Program Technology. As between the Parties, Aptose shall have
the sole right to prepare, file, prosecute and maintain Patents in the Aptose Program Technology, at Aptose’s sole cost and
expense.

 

(c)              
Filing, Prosecution and Maintenance of Patents in Joint Technology. Aptose will have the first right to prepare, file,
prosecute and maintain Patents in the Joint Technology (“Joint Patents”),at its sole cost and expense. Aptose
shall (A) notify CG in writing with respect to all significant developments regarding the Joint Patents, (B) promptly provide CG
with a copy of each material communication from any patent authority regarding the Joint Patents, and (C) provide CG with drafts
of each material filing (including draft patent applications and responses to office actions and similar filings) with respect
to the Joint Patents a reasonable amount of time in advance of the anticipated filing date and shall consider CG’s reasonable
comments thereto in good faith. Aptose shall notify CG of any decision to cease prosecution and/or maintenance of any Joint Patent
in any country. Aptose shall, to the extent practicable, provide such notice at least thirty (30) days prior to any filing or payment
due date, or any other due date that requires action in order to avoid loss of rights, in connection with such Joint Patent. In
such event, Aptose shall permit CG, at its discretion and expense, to continue prosecution or maintenance of such Joint Patent
in such country.

    	 	32	 

     

    

(d)             
Cooperation. Each Party shall provide the other Party all reasonable assistance and cooperation, at the other Party’s
request and expense, in the patent prosecution efforts provide above in this Section 8.2, including providing any necessary powers
of attorney, executing any other required documents or instruments for such prosecution, and making its personnel with appropriate
scientific expertise available to assist in such efforts.

 

8.3             
Patent Enforcement.

 

(a)              
If either Party becomes aware of any infringement or threatened infringement by a Third Party of any CG Patent on account
of a Third Party’s manufacture, use or sale of a Licensed Compound or Product, or any declaratory judgment or equivalent
action challenging any CG Patent in connection with any such infringement (a “Product Infringement”),
it will notify the other Party in writing to that effect. Any such notice shall include evidence to support an allegation of infringement
or threatened infringement, or declaratory judgment or equivalent action, by such Third Party.

 

(b)             
Aptose shall have the exclusive right, but not the obligation, to bring a suit or otherwise take action against any
Product Infringement in the Licensed Territory, at its own expense and by counsel of its own choice; provided, however, if Aptose
elects not to bring a suit or otherwise take action against any Product Infringement in the Licensed Territory, then unless Aptose
has a good faith, commercially reasonable reason not to enforce the applicable CG patents, the reduction in royalties for entry
of a Generic Product as set forth in Section 7.2(d) (Generic Entry) will not apply. CG shall cooperate with and provide reasonable
assistance to Aptose in such enforcement, at Aptose’s request and expense. CG further agrees to join, at Aptose’s expense,
any such action brought by Aptose under this Section 8.3 as a party plaintiff if required by Applicable Laws to pursue such action.
Aptose shall keep CG regularly informed of the status and progress of such enforcement efforts.

 

(c)              
Any recovery obtained by Aptose in connection with or as a result of any action against a Product Infringement, whether
by settlement or otherwise, shall first reimburse Aptose for any of its out-of-pocket costs and attorney fees, followed by CG for
any of its out-of-pocket costs and attorney fees, then four percent (4%) of the balance be paid to CG, and any remaining balance
be retained by Aptose.

 

(d)             
Aptose may exercise any of its rights under this Section 8.3 through an Affiliate or Sublicensee.

 

(e)              
As between the Parties, Aptose shall have the exclusive right, but not the obligation, to bring a suit or otherwise
take action against any infringement or threatened infringement of any Patent in the Aptose Program Technology worldwide, and shall
first reimburse Aptose for any of its out-of-pocket costs and attorney fees, followed by CG for any of its out-of-pocket costs
and attorney fees, then four percent (4%) of the balance be paid to CG, and any remaining balance be retained by Aptose. CG shall
cooperate with and provide reasonable assistance to Aptose in such enforcement, at Aptose’s request and expense.

 

8.4             
Trademarks. Aptose shall have the right to select the trademarks to be used in connection with the commercialization
of Products in the Field in the Licensed Territory (each, a “Product Trademark”), and shall have all
rights in and to such Product Trademarks in the Licensed Territory. Aptose will be responsible for the filing, prosecution, maintenance
and defense of all registrations of the Product Trademarks, and will be responsible for the payment of any costs relating to filing,
prosecution, maintenance and defense of all Product Trademarks. CG shall not select a trademark that is confusingly similar to
the Product Trademarks for use in promoting any product in the Licensed Territory or Retained Territory or file or otherwise seek
to establish rights in any Product Trademark in the Licensed Territory or any similar trademark in the Retained Territory.

    	 	33	 

     

    

article
9 

 

Confidentiality

 

9.1             
Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties,
the Parties agree that, during the Term and for ten (10) years thereafter, the receiving Party shall keep confidential and shall
not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any
Confidential Information of the other Party, and both Parties shall keep confidential and, subject to Sections 9.2, 9.3 and 9.5,
shall not publish or otherwise disclose the terms of this Agreement. Each Party may use the other Party’s Confidential Information
only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations.
Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own
(but no less than reasonable care) to ensure that its employees, agents, consultants, contractors and other representatives do
not disclose or make any unauthorized use of the Confidential Information of the other Party. Each Party will promptly notify the
other upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.

 

9.2             
Exceptions. Notwithstanding anything to the contrary in this Agreement, Confidential Information shall not include any
information that the receiving Party can prove by competent written evidence: (a) is now, or hereafter becomes, through no
act or failure to act on the part of the receiving Party, generally known or available to the public; (b) is known by the
receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates,
employees, agents, consultants or contractors; (c) is hereafter furnished to the receiving Party without restriction by a
Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or (d) is
independently discovered or developed by the receiving Party without the use of Confidential Information belonging to the disclosing
Party. Notwithstanding anything to the contrary in this Agreement, a receiving Party shall not be liable to the disclosing Party
for the use of Residuals (defined below) from Confidential Information of the disclosing Party, provided that the receiving Party
no longer has use of or access to any embodiment of such Confidential Information. This right to Residuals does not represent a
license under any patents, trade secret rights, copyrights or other intellectual property rights of the disclosing Party. The term
“Residuals” means any information that is retained in the unaided memories of the receiving Party’s employees
who have had access to the disclosing Party’s Confidential Information pursuant to the terms of this Agreement and who does
not and cannot identify such information as the Confidential Information of the disclosing Party.

    	 	34	 

     

    

9.3             
Authorized Disclosure.

 

(a)              
Each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably
necessary to:

 

(i)                
prosecute or defend litigation with respect to this Agreement; or

 

(ii)             
comply with Applicable Laws.

 

(b)             
Additionally, Aptose may use and disclose Confidential Information belonging to CG to the extent such use or disclosure:

 

(i)                
is necessary or useful for the prosecution or enforcement of CG Patents or patents or patent applications relating to
Products or for Regulatory Filings for Products;

 

(ii)             
is to Aptose’s officers, directors, employees, consultants or Affiliates, who agree to be bound by similar terms
of confidentiality; or

 

(iii)           
is to Aptose’s bona fide potential or actual contractors, Sublicensees, investors, investment bankers,
acquirers, merger partners, or other potential or actual financial partners; provided that in connection with such disclosure,
Aptose shall use all reasonable efforts to inform each disclose of the confidential nature of such Confidential Information and
cause each disclose to treat such Confidential Information as confidential.

 

(c)              
Additionally, CG may use and disclose Confidential Information belonging to Aptose to the extent such use or disclosure:

 

(i)                
is necessary or useful for Regulatory Filings for Products;

 

(ii)             
is to CG’s officers, directors, employees, consultants or Affiliates, who agree to be bound by similar terms of
confidentiality; or

 

(iii)           
is to CG’s bona fide potential or actual contractors, licensees, investors, investment bankers, acquirers,
merger partners, or other potential or actual financial partners; provided that in connection with such disclosure, CG shall use
all reasonable efforts to inform each disclose of the confidential nature of such Confidential Information and cause each disclose
to treat such Confidential Information as confidential.

 

(d)             
Notwithstanding Section 9.3(a), in the event a Party is required to make a disclosure of the other Party’s Confidential
Information pursuant to Section 9.3(a)(ii), it will, except where impracticable, give reasonable advance notice to the other Party
of such disclosure and use commercially reasonable efforts to secure confidential treatment of such information.

 

9.4             
Publication. CG shall not publish peer reviewed manuscripts, or provide other forms of public disclosure, including
abstracts and presentations, of results of studies or activities with respect to any Licensed Compound or Product in the Licensed
Territory without the prior written consent of Aptose, which shall not be unreasonably withheld. CG shall have the right to publish
peer reviewed manuscripts, or provide other forms of public disclosure, including abstracts and presentations, of results of studies
or activities with respect to any Licensed Compound or Product in any Retained Territory; provided, that CG shall provide each
such disclosure to Aptose reasonably in advance of submission or public disclosure thereof for Aptose’s review and comment
and shall reference Aptose in any such disclosure; and provided further that CG shall not publish any data in the CG Know-How in
existence as of the Effective Date before Aptose’s publication thereof, unless otherwise agreed by Aptose in advance in writing.
Aptose shall have the right to publish peer reviewed manuscripts, and provide other forms of public disclosure, including abstracts
and presentations, of results of studies and activities with respect to any Licensed Compound or Product, including any data and
results of studies of CG’806 included in the CG Know-How; provided that (a) during the Option Period, Aptose shall provide
each such disclosure to CG reasonably in advance of submission or public disclosure thereof for CG’s review and comment and
shall reference CG in any such disclosure, and shall not publish any CG Know-How, other than data and results of studies of CG’806,
without CG’s prior written consent, not to be unreasonably withheld; and (b) during the License Period, Aptose shall provide
CG with a copy of each such disclosure in advance of publication or other public disclosure thereof.

    	 	35	 

     

    

9.5             
Publicity; Public Disclosures. In the event that Aptose pays the Option Grant Fee, the Parties agree to issue a joint
press release substantially in a form agreed by the Parties. It is understood that each Party may desire or be required to issue
subsequent press releases relating to this Agreement or activities hereunder. The Parties agree to consult with each other reasonably
and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, to the extent practicable,
provided that a Party may not unreasonably withhold, condition or delay consent to such releases, and that either Party may issue
such press releases or make such disclosures as it determines, based on advice of counsel, are reasonably necessary to comply with
Applicable Laws, including regulations applicable to the public sale of securities, or for appropriate market disclosure. Each
Party shall provide the other Party with advance notice of legally required disclosures to the extent practicable. The Parties
will consult with each other on the provisions of this Agreement to be redacted in any public filings made by a Party as otherwise
required by Applicable Laws; provided that each Party shall have the right to make any such filing as it reasonably determines
necessary under Applicable Laws. In addition, following the initial joint press release announcing this Agreement, either Party
shall be free to disclose, without the other Party’s prior written consent, the existence of this Agreement, the identity
of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance herewith.

 

9.6             
Prior Confidentiality Agreement. As of the Effective Date, the terms of this Article 9 shall supersede any prior non-disclosure,
secrecy or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement, including
the Prior CDA and the confidentiality provisions of the MTA. Any information disclosed pursuant to any such prior agreement shall
be deemed Confidential Information for purposes of this Agreement.

 

9.7             
Equitable Relief.  Given the nature of the Confidential Information and the competitive damage that a Party would suffer
upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary
damages may not be a sufficient remedy for any breach of this Article 9. In addition to all other remedies, a Party shall be entitled
to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this
Article 9.

    	 	36	 

     

    

article
10

 

Representations
And Warranties

 

10.1         
Representations and Warranties of Aptose. Aptose hereby represents and warrants to CG that, as of the Effective Date:

 

(a)              
Corporate Existence and Power. Aptose is a corporation duly organized, validly existing and in good standing under the
laws of the jurisdiction in which it is incorporated and has full power and authority and the legal right to own and operate its
property and assets and to carry on its business as it is now being conducted and as contemplated by this Agreement.

 

(b)             
Authority and Binding Agreement. (i) Aptose has the power and authority and the legal right to enter into this Agreement
and perform its obligations hereunder; (ii) Aptose has taken all necessary authorized action on its part required to authorize
the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been
duly executed and delivered on behalf of Aptose and constitutes a legal, valid and binding obligation that is enforceable against
it in accordance with its terms.

 

10.2         
Representations and Warranties of CG. CG hereby represents and warrants to Aptose that, as of the Effective Date, and
hereby covenants that:

 

(a)              
Corporate Existence and Power. CG is a corporation duly organized, validly existing and in good standing under the laws
of the jurisdiction in which it is incorporated and has full power and authority and the legal right to own and operate its property
and assets and to carry on its business as it is now being conducted and as contemplated by this Agreement.

 

(b)             
Authority and Binding Agreement. (i) CG has the power and authority and the legal right to enter into this Agreement
and perform its obligations hereunder; (ii) CG has taken all necessary authorized action on its part required to authorize the
execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly
executed and delivered on behalf of CG and constitutes a legal, valid and binding obligation that is enforceable against it in
accordance with its terms.

 

(c)              
Title; Encumbrances. CG is the sole owner of the entire right, title and interest in and to all patents, patent applications
and other intellectual property rights within the CG Intellectual Property, free and clear from any mortgages, pledges, liens,
security interests, conditional and installment sale agreements, encumbrances, charges or claims of any kind. CG has the full and
legal right and authority to license to Aptose the CG Intellectual Property;

 

(d)             
Exhibit A. Exhibit A accurately identifies all Patents owned by or licensed to CG or any of its Affiliates as
of the Effective Date that are necessary or useful for the research, development, manufacture, use or sale of any BTK inhibitor.
CG Controls all such Patents.

    	 	37	 

     

    

(e)              
Prior Licenses and Assignments. CG has not prior to the Effective Date assigned or licensed, and will not during the
Term assign or license, to any person or entity any Information or intellectual property (including Patents) that is or could reasonably
be expected to be necessary or useful for the research, development, manufacture, use or sale of any Licensed Compound or Product
in the Field in the Licensed Territory.

 

(f)               
No Conflict. CG has not entered, and shall not enter, into any agreement with any Third Party that is in conflict with
the rights granted to Aptose under this Agreement, and has not taken and shall not take any action that would in any way prevent
it from granting the rights granted to Aptose under this Agreement, or that would otherwise materially conflict with or adversely
affect Aptose’s rights under this Agreement. CG’s performance and execution of this Agreement does not and will not
result in a breach of any other contract to which it is a party. As of the Effective Date, CG is aware of no action, suit, inquiry
or investigation instituted by any Third Party that threatens the validity of this Agreement.

 

(g)              
Validity and Enforceability. CG is not aware of the existence of any facts that could form the basis for the invalidation
or unenforceability of any CG Patent.

 

(h)             
Notice of Infringement. CG has not received any notice or threat from any Third Party asserting or alleging, nor does
CG have any knowledge of any basis for any assertion or allegation, that any research, manufacture or development of Licensed Compounds
or Products by CG prior to the Effective Date infringed the intellectual property rights of such Third Party;

 

(i)                
Notice of Misappropriation. CG has not received any notice or threat from any Third Party asserting or alleging, and
there is no basis for any assertion or allegation, that any research, manufacture or development of Licensed Compounds or Products
by CG prior to the Effective Date misappropriated the intellectual property rights of such Third Party;

 

(j)               
Third Party Intellectual Property. To CG’s knowledge, (i) the research, manufacture, Development and Commercialization
of any Licensed Compound in the Field in the Licensed Territory will not infringe or misappropriate the intellectual property rights
of any Third Party and (ii) there are no pending Third Party patent applications that, if issued with the published or currently
pending claims, would be infringed by the manufacture, Development or Commercialization of Licensed Compounds.

 

(k)             
Third Party Infringement. To CG’s knowledge, no Third Party is infringing or has infringed any CG Patents or has
misappropriated any CG Know-How;

 

(l)                
No Proceeding. There are no pending, and to CG’s knowledge, no threatened, adverse actions, suits or proceedings
(including interferences, reissues, reexaminations, cancellations, oppositions, nullity actions, invalidation actions or post-grant
reviews) against CG involving the CG Intellectual Property or Licensed Compounds;

 

(m)           
Full Disclosure. To CG’s knowledge, all written data, results and other information disclosed at any time prior
to the Effective Date by CG relating to the CG Intellectual Property or any Licensed Compound or Product are true and accurate.
Additionally, CG has not failed prior to the Effective Date and will not fail during the Term to disclose to Aptose any material
information known to CG that relates to the CG Intellectual Property or any Licensed Compound or Product, or that would be required
to be disclosed in order to make the data, results, and other information relating to the CG Intellectual Property or any Licensed
Compound or Product that have been disclosed by CG not misleading.

    	 	38	 

     

    

10.3         
Additional Representations and Warranties.

 

(a)              
By Aptose. Aptose hereby represents and warrants to CG that, as of the Execution Date, Aptose has not entered into any
agreement or arrangement with a Third Party that impairs Aptose’s ability to assign any Data pursuant to Aptose’s obligations
under Sections 2.6 (Effects of Aptose’s Failure to Pay Option Grant Fee), 3.9 (Effects of Aptose’s Failure to Exercise
Option) and 12.4 (Results of Termination), and any other similar provisions in this Agreement.

 

(b)             
By CG. CG hereby represents and warrants to Aptose that, as of the Execution Date, the Patents listed in Exhibit
A comprise all of CG’s BTK-related Patents. CG hereby further covenants with Aptose that the know-how CG is obligated
to transfer under Section 3.5 (Technology Transfer and Access to Data) will comprise all of CG’s know-how pertaining to BTK
inhibitors.

 

10.4         
Disclaimers. Except as otherwise set forth in SECTION 3.8(B) AND IN this ARTICLE
10, neither Party makes, and each Party hereby disclaims, any and all representations and warranties of any kind, express or implied,
with respect to the subject matter of this Agreement, including warranties of merchantability, fitness for a particular purpose
and non-infringement and any warranty arising out of prior course of dealing and usage of trade.

 

article
11 

 

Indemnification

 

11.1         
Indemnification by Aptose. Aptose hereby agrees to indemnify, defend and hold harmless CG, its Affiliates, and all of
their respective officers, directors, employees and agents and their respective successors, heirs and assigns (collectively, the
“CG Indemnitees”) from and against all liabilities, damages, expenses and/or loss, including reasonable
legal expenses and attorneys’ fees (collectively, “Losses”), to which any CG Indemnitee may become
subject as a result of any Third Party suits, claims, actions, proceedings and demands (collectively, “Claims”)
against a CG Indemnitee to the extent arising from: (a) Aptose’s or its Affiliates’, contractors’, licensees’,
or Sublicensees’ research, Development, manufacturing, use or Commercialization of Licensed Compounds or Products in the
Field in the Licensed Territory; (b) any Aptose Indemnitee’s negligence, recklessness or intentional misconduct; or (c) Aptose’s
breach of any obligation, representation, warranty or covenant in this Agreement, except, in each case (a)-(c), to the extent such
Losses arise from the negligence, recklessness or intentional misconduct of any CG Indemnitee or the breach by CG of any obligation,
representation, warranty or covenant in this Agreement.

    	 	39	 

     

    

11.2         
Indemnification by CG. CG hereby agrees to indemnify, defend and hold harmless Aptose, its Affiliates, and all of their
respective officers, directors, employees and agents and their respective successors, heirs and assigns (collectively, the “Aptose
Indemnitees”) from and against all Losses to which any Aptose Indemnitee may become subject as a result of any Third
Party Claims against an Aptose Indemnitee to the extent arising from: (a) CG’s or its Affiliates’, contractors’
or licensees’ research, Development, manufacturing, use or Commercialization of Licensed Compounds or Products prior to the
Effective Date, or in the Retained Territory; (b) any CG Indemnitee’s negligence, recklessness or intentional misconduct;
or (c) CG’s breach of any obligation, representation, warranty or covenant in this Agreement, except, in each case (a)-(c),
to the extent such Losses arise from the negligence, recklessness or intentional misconduct of any Aptose Indemnitee or the breach
by Aptose of any obligation, representation, warranty or covenant in this Agreement.

 

11.3         
Procedure. A party that intends to claim indemnification under this Article 11 (the “Indemnitee”)
shall promptly notify the indemnifying Party (the “Indemnitor”) in writing of any Third Party Claim in
respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense
or settlement thereof. The Indemnitee may participate at its expense in the Indemnitor’s defense of and settlement negotiations
for any Claim with counsel of the Indemnitee’s own selection. The indemnity arrangement in this Article 11 shall not
apply to amounts paid in settlement of any action with respect to a Claim, if such settlement is effected without the consent of
the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor
within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor
of its indemnification obligations under this Article 11 if and to the extent the Indemnitor is actually prejudiced thereby.
The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with
respect to a Claim covered by this indemnification.

 

article
12

Term; Termination

 

12.1         
Term. The term of this Agreement (the “Term”) shall commence upon the Effective Date and,
unless terminated earlier pursuant to this Article 12, shall remain in effect, on a Product-by-Product and country-by-country basis,
until the expiration of the Royalty Term with respect to such Product in such country. Upon the expiration of this Agreement with
respect to a Product and country, the licenses granted to Aptose under this Agreement with respect to such Product and country
shall become fully-paid, perpetual and irrevocable.

 

12.2         
Termination by Aptose.

 

(a)              
Aptose may terminate this Agreement in its entirety, without cause, (a) during the Evaluation Period, (b) during the
Option Period or (c) during the License Period, upon thirty (30) days prior written notice to CG. Except as otherwise set forth
in Section 12.2(b) below, Aptose shall have no right to terminate this Agreement without cause during the License Period.

    	 	40	 

     

    

(b)             
Aptose may terminate this Agreement in its entirety during the License Period, upon thirty (30) days prior written notice
to CG, in the event (i) Aptose reasonably determines that it is unsafe to continue the clinical studies or commercialization of
the Licensed Compound or Product, or (ii) circumstances beyond Aptose’s reasonable control prevent completion of such clinical
studies, and commercialization of the Licensed Compound or Product, including without limitation, failure to demonstrate clinical
effectiveness by failing to meet the primary endpoint in any such clinical study as set forth in the protocol therefor.

 

12.3         
Termination by Either Party for Material Breach.

 

(a)              
Breach. Subject to Sections 12.3(b) and (c), each Party shall have the right to terminate this Agreement upon written
notice to the other Party if such other Party materially breaches its obligations under this Agreement and, after receiving written
notice from the non-breaching Party identifying such material breach in reasonable detail, fails to cure such material breach within
sixty (60) days from the date of such notice; provided that if such breach is not reasonably capable of cure within such sixty
(60)-day period, the breaching Party may submit a reasonable cure plan prior to the end of such sixty (60)-day period, in which
case the other Party shall not have the right to terminate this Agreement for so long as the breaching Party is using diligent
efforts to implement such cure plan.

 

(b)             
Disputed Breach. If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified
in a notice provided by the other Party in accordance with Section 12.3(a), and such alleged breaching Party provides the other
Party notice of such dispute within such sixty (60)-day period, then the non-breaching Party shall not have the right to terminate
this Agreement under Section 12.3(a) unless and until the arbitrators, in accordance with Article 13 (Governing Law; Dispute Resolution),
have determined that the alleged breaching Party has materially breached this Agreement and such Party fails to cure such breach
within sixty (60) days following such arbitrators’ decision. It is understood and agreed that during the pendency of such
dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all
of their respective obligations hereunder.

 

(c)              
Disfavored Remedy. The Parties agree that from and after Aptose’s payment of the first milestone payment under
Section 7.1(a), termination pursuant to this Section 12.3 is a remedy to be invoked only if the breach cannot be adequately remedied
through a combination of specific performance during a period of sixty (60) days or less, or otherwise in a manner that the arbitrators
under Section 13.4 determine is fair and reasonable to the non-breaching Party, and the payment of money damages.

 

12.4         
Results of Termination. Upon any early termination (i.e., not upon expiration) of this Agreement by Aptose pursuant
to Section 12.2 (Termination by Aptose) or by Aptose or CG pursuant to Section 12.3 (Termination by Either Party for Material Breach):

 

(a)              
all licenses granted to Aptose under this Agreement will terminate, including the license granted by CG to Aptose under
Section 4.5 (Commercial License Grant) above;

    	 	41	 

     

    

(b)             
Aptose shall diligently wind down, in accordance with Applicable Laws, all Development activities it is conducting for
Products in the Licensed Territory at the time of notice of such termination;

 

(c)              
Aptose shall transfer and assign to CG all Regulatory Filings and Regulatory Approvals for Products in the Licensed
Territory, and all of its right, title and interest in and to the Aptose Data, Aptose Program Technology and Joint Technology that
is solely related to Licensed Compounds Developed by Aptose under this Agreement, or that is solely an improvement, enhancement
or modification to such Licensed Compounds;

 

(d)             
Aptose shall assign to CG all of its right, title and interest in and to any and all Product Trademarks, including all
goodwill therein;

 

(e)              
Aptose shall transfer the patent files for all CG Patents in the Licensed Territory to CG; and

 

(f)               
Aptose agrees to grant, and hereby grants, to CG, effective only upon termination of this Agreement, an exclusive, royalty-free,
fully-paid license, with the right to grant sublicenses through multiple tiers, under all such Aptose Program Technology and Aptose’s
interest in and to the Joint Technology, that is not solely related to Licensed Compounds Developed by Aptose under this Agreement,
or that is not solely an improvement, enhancement or modification to such Licensed Compounds, to develop, make, have made, use,
import, export, offer for sale and sell Licensed Compounds and Products in the Field in the Licensed Territory and the Retained
Territory.

 

12.5         
Sublicense Survival. Upon termination of this Agreement by CG pursuant to Section 12.3 (Termination by Either Party
for Material Breach) and provided that the first Phase 2 Clinical Trial of a Product has been initiated by Aptose and the corresponding
milestones has been paid in accordance with Section 7.1(a) (Development Milestones), any sublicense granted by Aptose under this
Agreement shall survive and shall automatically be assigned by Aptose to CG such that such sublicense becomes a direct license
between CG and such Sublicensee on the same terms and conditions as those set forth in this Agreement, to the extent applicable
to the rights granted by Aptose to such Sublicensee, provided that such sublicense was granted in accordance with the terms of
Section 4.5 (Sublicenses) and that such Sublicensee is in compliance with the terms of the sublicense agreement and agrees to comply
with all applicable terms of this Agreement.

 

12.6         
Accrued Obligations; Survival. Termination or expiration of this Agreement for any reason shall not release a Party
from any liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any
provision hereto to the extent it is expressly stated to survive such termination. The following provisions shall survive any expiration
or termination of this Agreement for a period of time specified therein, or if not specified, then they shall survive indefinitely:
Sections 3.9, 3.10, 7.6, 7.7, 8.1, 10.4, 12.4, 12.5, 12.6, 12.7, 14.1, 14.7, 14.8, 14.10 and Articles 9, 11 and 13.

 

12.7         
Return of Confidential Information. Upon expiration or termination of this Agreement, except to the extent that a Party
obtains or retains the right to use the other Party’s Confidential Information, each Party shall promptly return to the other
Party, or delete or destroy, all relevant records and materials in such Party’s possession or control containing Confidential
Information of the other Party; provided that such Party may keep one copy of such materials for archival purposes only subject
to continuing confidentiality obligations.

    	 	42	 

     

    

12.8         
Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by one Party to the other
Party are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or comparable provision
of applicable bankruptcy or insolvency laws, licenses of right to “intellectual property” as defined under Section 101
of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. The Parties agree that a Party
that is a licensee of such rights under this Agreement will retain and may fully exercise all of its rights and elections under
the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. The Parties further agree that, in
the event of the commencement of a bankruptcy proceeding by or against a Party to this Agreement under the U.S. Bankruptcy Code
or comparable provision of applicable bankruptcy or insolvency laws, the other Party will be entitled to a complete duplicate of
(or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same,
if not already in its possession, will be promptly delivered to it (a) upon any such commencement of a bankruptcy or insolvency
proceeding upon its written request therefor, unless the bankrupt Party elects to continue to perform all of its obligations under
this Agreement, or (b) if not delivered under (a) above, following the rejection of this Agreement by or on behalf of the
bankrupt Party upon written request therefor by the other Party.

 

article
13 

Governing Law; Dispute Resolution

 

13.1         
Governing Law. This Agreement shall be governed by the laws of the State of New York, U.S., without giving effect to
any conflicts of laws principles that would require the application of other law.

 

13.2         
Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the term of this
Agreement that relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish
procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and
without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article
13 to resolve any controversy or claim arising out of, relating to or in connection with any provision of this Agreement, if and
when a dispute arises under this Agreement.

 

13.3         
Internal Resolution. With respect to all disputes arising between the Parties under this Agreement, including, without
limitation, any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement,
if the Parties are unable to resolve such dispute within thirty (30) days after such dispute is first identified by either Party
in writing to the other, the Parties shall refer such dispute to the Chief Executive Officer of CG and the Chief Executive Officer
of Aptose (collectively, the “Executive Officers”) for attempted resolution by good faith negotiations,
including at least one in-person meeting, within thirty (30) days after the dispute is referred to them. If the matter is not resolved
within thirty (30) days following the written referral to the Executive Officers, either Party may then invoke the provisions of
Section 13.4 (Arbitration) below.

    	 	43	 

     

    

13.4         
Arbitration.

 

(a)              
Any dispute that is not resolved pursuant to Section 13.3 (Internal Resolution), except for a dispute, claim or controversy
subject to Section 13.4(h), shall be settled by binding arbitration administered by Federal Arbitration before three (3) arbitrators
pursuant to the FedArb Rules and Procedures then in effect (the “Rules”), except as otherwise provided
herein. The arbitration shall be governed by the U.S. Federal Arbitration Act, 9 U.S.C. §§ 1-16 (the “Federal
Arbitration Act”), to the exclusion of any inconsistent state laws. The arbitration will be conducted in San Francisco,
California, and the Parties consent to the personal jurisdiction of the U.S. federal courts for any case arising out of or otherwise
related to the arbitration, its conduct and its enforcement. The language to be used in the arbitral proceedings will be English.
Any situation not expressly covered by this Agreement shall be decided in accordance with the Rules, as supplemented by discovery
pursuant to the U.S. Federal Rules of Civil Procedures.

 

(b)             
The arbitrators shall issue a reasoned opinion following a full comprehensive hearing, no later than twelve (12) months
following the selection of the arbitrators.

 

(c)              
Any award shall be promptly paid in Dollars free of any tax, deduction or offset; and any costs, fees or taxes incident
to enforcing the award shall, to the maximum extent permitted by law, be charged against the Party resisting enforcement. If as
to any issue the arbitrators should determine under Applicable Laws that the position taken by a Party is frivolous or otherwise
irresponsible or that any wrongdoing it finds is in callous disregard of law and equity or the rights of the other Party, the arbitrators
shall also be entitled to award an appropriate allocation of the adversary’s reasonable attorney fees, costs and expenses
to be paid by the offending Party, the precise sums to be determined after a bill of attorney fees, expenses and costs consistent
with such award has been presented following the award on the merits. Each Party agrees to abide by the award rendered in any arbitration
conducted pursuant to this Article 13, and agrees that, subject to the Federal Arbitration Act, judgment may be entered upon the
final award in the Federal District Court in the Northern District of California and that other courts may award full faith and
credit to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred
for breach of this Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrators.

 

(d)             
Except as set forth in Section 13.4(c), each Party shall bear its own legal fees. The arbitrators shall assess their
costs, fees and expenses against the Party losing the arbitration unless they believe that neither Party is the clear loser, in
which case the arbitrators shall divide their fees, costs and expenses according to their discretion.

 

(e)              
Provided a Party has made a sufficient showing under the rules and standards set forth in the U.S. Federal Rules of
Civil Procedure and applicable case law, the arbitrators shall have the freedom to invoke, and the Parties agree to abide by, injunctive
measures after either Party submits in writing for arbitration claims requiring immediate relief. Additionally, nothing in this
Article 13 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent
jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute
either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending
the arbitration proceeding.

    	 	44	 

     

    

(f)               
The arbitration proceeding will be confidential and the arbitrators shall issue appropriate protective orders to safeguard
each Party’s Confidential Information. Except as required by Applicable Laws, no Party shall make (or instruct the arbitrators
to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written consent of
the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties
and the arbitrators, except as required in connection with the enforcement of such award or as otherwise required by Applicable
Laws.

 

(g)              
Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement
for any reason.

 

(h)             
Any dispute, controversy or claim relating to the validity, enforceability or inventorship of any patents or trademarks
shall be submitted to a court of competent jurisdiction in the country in which such patent or trademark rights were granted or
arose.

 

article
14

General Provisions

 

14.1         
Notices. All notices required or permitted hereunder shall be in writing and sufficient if delivered personally, sent
by internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested,
addressed as follows.

All notices to Aptose
shall be addressed as follows:

 

Aptose Biosciences,
Inc.

3 Lagoon Dr.,
Suite #120

Redwood City,
CA 94065

Attn: Avanish Vellanki

 

With copies to (which shall not
constitute notice):

 

Aptose Biosciences,
Inc.

5955 Airport
Road, Suite #228

Mississauga,
ON L4V 1R9

Canada

Attn: Dr. William G. Rice

 

    	 	45	 

     

    

Cooley LLP

3175 Hanover Street

Palo Alto, California 94304

USA

Attn: Robert L. Jones

 

All notices to CG shall be addressed as
follows:

 

CrystalGenomics,
Inc.

5th
F. Bldg. A, Korea Bio Park

700 Daewangpangyo-ro,
Bundang-gu, Seongnam-si

Gyeonggi-do,
463-400 Korea

Attn: Steven Kim

 

With a copy to (which shall not constitute notice):

 

Morrison & Foerster LLP

425 Market Street, 32nd Floor

San Francisco, CA 94105

Attn: Key Shin

 

or to such other address as the Party to
whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed
to have been given: (a) when delivered if personally delivered on a Business Day; (b) on the Business Day after dispatch
if sent by internationally-recognized overnight courier; and (c) on the third Business Day following the date of mailing if
sent by mail.

 

14.2         
Force Majeure. No Party shall be liable for any delay or failure of performance to the extent such delay or failure
is caused by circumstances beyond its reasonable control and that by the exercise of due diligence it is unable to prevent, provided
that the Party claiming excuse uses its commercially reasonable efforts to overcome the same.

 

14.3         
Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties relating to the subject
matter contained herein and merges all prior discussions and agreements between them (including the Prior CDA), and no Party shall
be bound by any representation other than as expressly stated in this Agreement; provided that the surviving provisions of the
MTA (other than the confidentiality provisions thereof) shall remain in effect in accordance with the terms of the MTA. This Agreement
may be amended only by a written instrument signed by authorized representatives of each of the Parties.

 

14.4         
Non-Waiver. The failure of a Party in any one or more instances to insist upon strict performance of any of the terms
and conditions of this Agreement shall not be construed as a waiver or relinquishment, to any extent, of the right to assert or
rely upon any such terms or conditions on any future occasion.

 

14.5         
Disclaimer of Agency. This Agreement shall not constitute any Party the legal representative of agent of another, nor
shall any Party have the right or authority to assume, create, or incur any Third Party liability or obligation of any kind, express
or implied, against or in the name of or on behalf of another except as expressly set forth in this Agreement.

    	 	46	 

     

    

14.6         
Severance. If any Article or part thereof of this Agreement is declared invalid by any court of competent jurisdiction,
then such declaration shall not affect the remainder of the Article or other Articles. To the extent possible the Parties shall
revise such invalidated Article or part thereof in a manner that will render such provision valid without impairing the Parties’
original interest.

 

14.7         
Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior
written consent of the other Party, except that a Party may make such an assignment or transfer without the other Party’s
consent to its Affiliates or to the successor to all or substantially all of the business of such Party to which this Agreement
relates (whether by merger, acquisition, consolidation, sale of assets or otherwise). Any permitted assignment shall be binding
on the successors, heirs and assigns of the assigning Party. Any assignment or attempted assignment by a Party in violation of
the terms of this Section 14.7 shall be null and void.

 

14.8         
Limitation of Liability. Except with respect to Either Party’s indemnity
obligatIons as set forth in ARTICLE 11 (INDEMNIFICATION) and to breachES of ARTICLE 9 (CONFIDENTIALITY), in no event shall either
Party be liable to the other party for incidental, consequential, indirect, punitive or special damages arising out of or related
to this Agreement, however caused, under any theory of liability, even if advised of the possibility of such damages. 

 

14.9         
Performance by Affiliates. Aptose may discharge any obligations and exercise any right hereunder through any of its
Affiliates. Aptose hereby guarantees the performance by its Affiliates of its obligations under this Agreement, and shall cause
its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by Aptose’s
Affiliate of any of its obligations under this Agreement shall be deemed a breach by Aptose, and CG may proceed directly against
Aptose without any obligation to first proceed against Aptose’s Affiliate.

 

14.10     
No Strict Construction; Headings. This Agreement has been prepared jointly by the Parties and shall not be strictly
construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of
which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in this Agreement
have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained
in the particular Article or Section. Except where the context otherwise requires, the use of any gender shall be applicable to
all genders, and the word “or” is used in the inclusive sense (and/or). The term “including” as used herein
means including, without limiting the generality of any description preceding such term. All references in this Agreement to the
singular shall include the plural where applicable. All references to days in this Agreement mean calendar days, unless otherwise
specified.

    	 	47	 

     

    

14.11     
Further Assurances. At any time or from time to time on and after the Effective Date, either Party shall at the request
of the other party (a) deliver to the requesting party such records, data or other documents consistent with the provisions
of this Agreement, (b) execute, and deliver or cause to be delivered, all such consents, documents or further instruments
of assignment, transfer or license, and (c) take or cause to be taken all such actions, as the requesting Party may reasonably
deem necessary or desirable in order for the requesting Party to obtain the full benefits of this Agreement and the transactions
contemplated hereby.

 

14.12     
English Language. All notices required or permitted to be given hereunder, and all written, electronic, oral or other
communications between the Parties regarding this Agreement shall be in the English language. This Agreement was prepared in the
English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement

 

14.13     
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be an original and all
of which shall constitute together the same document.

 

Signature Page to Follow

 

 

 

 

 

     

     

    

In
Witness Whereof, the Parties hereto have caused this Agreement to be signed by their duly authorized representatives
as of the Execution Date.

 

	Aptose Biosciences Inc.	 	CrystalGenomics, Inc.
	 	 	 	 	 
	 	 	 	 	 
	/s/ Avanish Vellanki

	 	/s/ Joong Myung Cho
	 	 	 	 	 
	Name:	Avanish Vellanki	 	Name:	Joong Myung Cho
	 	 	 	 	 
	Title:	SVP, Chief Business Officer	 	Title:	CEO
	 	 	 	 	 
	Date:	March 24, 2016	 	Date:	3/25/16

 

 

 

 

 

 

 

 

 

 

    Signature Page of Option and License Agreement

     

    

Exhibit A

 

CG Patents 

 

	Country	Application No.	Title	Status
	USA	
        US 61/746,980

        (Provisional Application for PCT/KR2013/012204)
	2,3-dihydro-isoindol-1-one DERIVATIVES AND METHODS OF USE THEREOF AS BTK INHIBITOR	
        Applied

        Dec. 28, 2012

	PCT	PCT/KR2013/012204	2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE THEREOF AS BTK INHIBITOR	
        Applied

        Dec. 26, 2013

	Korea	KR 10-2015-7018342	(2,3-dihydro-isoindol-1-one DERIVATIVE AS BTK KINASE SUPPRESSANT, ANd pharmaceutical composition including the same)	
        Applied

        Jul. 08, 2015

	Europe	EP 13 867 650.7	2,3-dihydro-isoindol-1-one DERIVATIVE AS BTK KINASE SUPPRESSANT, ANd pharmaceutical composition including the same	
        Applied

        Jul. 23, 2015

	USA	US 14655954	2,3-dihydro-isoindol-1-one DERIVATIVE AS BTK KINASE SUPPRESSANT, ANd pharmaceutical composition including the same	
        Applied

        Jun. 26, 2015

	Australia	AU 2013371146	2,3-dihydro-isoindol-1-one DERIVATIVE AS BTK KINASE SUPPRESSANT, ANd pharmaceutical composition including the same	
        Applied

        Jun. 29, 2015

	Brazil	BR 11 2015 015477 8	
        DERIVADOS DE 2,3-DI-HIDRO-ISOINDOL-1-ONA E MÉTODOS DE
        USO

        DOS MESMOS COMO INIBIDORES DE BTK
	
        Applied

        Jun 25, 2015

	Russia	RU 2015124381	
        2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES AND

        METHODS OF USE THEREOF AS BTK INHIBITOR
	
        Applied

        Jun. 23, 2015

 

     

     

    

	Canada	CA 2 896 711	2,3-dihydro-isoindol-1-one DERIVATIVES AND METHODS OF USE THEREOF AS BTK INHIBITOR	
        Applied

        Jun. 27, 2015

	China	
        201380068623.6

        (Publication No. CN 104995184)
	BTK kinase inhibitors as 2, 3-dihydro-indole-1-one of the conductor and the trap containing such pharmaceutical compositions	
        Applied

        Jun. 26, 2015

	Japan	2015-550315	
        2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES AND

        METHODS OF USE THEREOF AS BTK INHIBITOR
	
        Applied

        Jun. 29, 2015

	Mexico	15/08396	DERIVATIVES OF 2,3-DIHYDRO-ISOINDOLE-1-ONE AS INHIBITORS OF BTK KINASE AND PHARMACEUTICAL COMPOSITIONS INCLUDE	
        Applied

        Jun. 26, 2015

	India	6610/DELNP/2015	2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE THEREOF AS BTK INHIBITOR	
        Applied

        Jul. 28, 2015

 

 

     

     

    

Exhibit B

 

Assay Protocols for Competing Product

 

 

Protocol to assess in vitro enzymatic potency against a standard
panel of kinases as typically used by a commercial testing laboratory that routinely performs such tests as part of its commercial
services offering. Additionally, assay results are to be rejected and re-performed if the measured IC50 values are lower than 50%
of the enzyme concentration used.

 

If there is a dispute between the Parties as to whether a product
satisfies the definition of Competing Product (as set forth in Section 1.19 above), such product will be submitted to an independent
Third Party testing laboratory selected from the list of approved laboratories set forth below or as mutually agreed upon by the
Parties at such time, and have such testing laboratory perform the test per the protocol guidelines set forth in this Exhibit
B. The Parties will share equally the cost of such testing.

 

List of approved Third Party testing laboratories to assess
in vitro enzymatic potency:

 

[*]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]